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ABSTRACT 
 
Following the ligation of Toll-like receptors (TLRs) by bacterial-derived signature 
molecules, innate immune cells such as monocytes, macrophages and neutrophils 
initiate the inflammatory process by secreting chemokines and cytokines with a wide 
range of immunomodulatory effects. Under normal conditions, these mediators work to 
compartmentalize the inflammatory process and eradicate the intruder, while 
simultaneously recruiting more immune cells to the site of infection. In sepsis, 
however, the virtues of this containment are lost as the response against a disseminated 
bacterial infection becomes systemic with an excessive production of cytokines that can 
lead to tissue injury, organ dysfunction and ultimately death. Here we have investigated 
TLR-induced cytokine secretion in vitro by monocytes and granulocytes from healthy 
donors and septic patients using the ELISpot and/or FluoroSpot assays. By looking at 
the secretion of cytokines directly ex vivo, the ELISpot assay offered the potential of 
being able to better define the immunological status of septic patients. We investigated 
the lipopolysaccharide (LPS)-induced cytokine secretion by peripheral blood 
mononuclear cells (PBMC) and granulocytes from healthy donors using the ELISpot 
assay. Cytokines (IL-1β, IL-6, IL-10, IL-12p40, TNF-α, GM-CSF) and chemokines 
(IL-8, MIP-1β) important in inflammatory processes were assessed. Granulocytes were 
found to selectively secrete IL-8 and MIP-1β. Also TNF-α was secreted but by 
considerably fewer cells. In contrast, PBMCs secreted all evaluated cytokines with 
CD14+ monocytes being the main source of production. Next, we analyzed the cytokine 
secretion by enriched monocytes from healthy donors in response to LPS and 
lipoteichoic acid (LTA). The FluoroSpot technique allowed for the simultaneous 
analysis of two cytokines from the same population of isolated cells. With this 
approach, a recurring pattern of cytokine co-secretion was observed, identifying several 
distinct cytokine-secreting profiles for the TNF-α-, GM-CSF-, IL-10-, IL-12p40-
secreting monocytes and those secreting IL-6 or IL-1β. Finally, the spontaneous and 
LPS-induced cytokine secretion by total leukocytes isolated from septic patients (n=32) 
and healthy controls (n=30) was evaluated using the ELISpot assay. Surprisingly, we 
found no increase in the number of constitutively cytokine-secreting cells from any of 
the septic patients despite significantly increased levels of cytokines (IL-6, IL-1β, TNF-
α, GM-CSF, IL-10, IL-12p40) in their plasma. Simultaneously, the LPS-induced in 
vitro capacity revealed a maintained (IL-6, TNF-α) as well as reduced (IL-1β, GM-
CSF, IL-10, IL-12p40) number of cytokine-secreting monocytes in the patients 
compared to normal donors. This selective reduction for some of the cytokines could be 
correlated with disease severity. In conclusion, our data indicate that circulating 
monocytes are not the major source of increased cytokine levels in patients with sepsis.    
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1 INTRODUCTION 
 
The role of microbes in infectious diseases is today common knowledge. However, the 
first schools of medicine were understandably challenged in explaining how these 
lethal illnesses could originate and be transmitted. Physicians in the middle ages spoke 
of an airborne poison as a reasonable explanation due to the similarities in symptoms of 
some infectious diseases and those seen after intoxication. The theory named this 
poison “miasma”, which was believed to originate as a noxious gas following the 
decomposition of organic material present within dying patients or in slow-moving 
waters such as swamps. An alternative viewpoint was that a poisonous material, termed 
“contagion” caused lethal illnesses and that this dangerous material originated in rotten 
fish or meat. Different from the theory of miasma, the contagion did not spread through 
the air, only by direct physical contact [1]. 
 
Although the two models of miasma and contagion failed to explain the true nature of 
infectious diseases, it was not until the 19th century that a causative connection was 
made to that of living microorganisms. At that time, Luis Pasteur demonstrated in a 
series of experiments that bacteria were responsible for the decay of organic material. 
Furthermore, he recognized that bacteria were not only capable of causing infectious 
disease but they were actually the single requirement for an infection to be initiated. 
Robert Koch went on to show how specific microorganisms gave rise to certain 
infectious diseases and laid out the principles for how to determine the causal 
relationship between the two [1]. Nevertheless, once science transitioned from a pre-
microbial to a post-microbial era, a new set of questions began to emerge [2]: How 
does the body recognize the bacteria? What kind of bacterial products elicits the bodily 
reactions associated with disease? 
 
Thankfully, due to great discoveries in innate immunity during the last 15 years, those 
questions have finally been answered at a molecular level [3]. We today understand 
how bacterial infections are perceived by the host and what kind of bacterial products 
are recognized, yet much work remains to be done in defining the nature of the 
response once it has been initiated and propagated throughout the complexity of a 
living organism. This need is perhaps best exemplified by the continued difficulties of 
finding good therapeutic options for patients overreacting to bacterial infections [4]. 
Understanding and balancing the adverse systemic inflammatory response in sepsis, 
severe sepsis and septic shock represents a major challenge that will require an even 
deeper knowledge of cytokines and how the innate immune system can be regulated. 
This thesis is an attempt to simply provide additional sentences to this unfinished story, 
focusing on the cellular immune response of monocytes in healthy donors and septic 
patients at the single cell level. 
 2 
2 BACKGROUND 
 
 
2.1 IMMUNOLOGY 
 
In jawed vertebrates, including animals like fish, amphibians, reptiles, mammals and 
birds, the defense system against foreign invaders is divided into two branches of 
immunity. One part, the innate immune system, is considered a first line of defense and 
is solely dependent on the encoded behavior passed down through our germ-line, i.e. its 
response is immediate, genetically pre-determined and present from the moment of 
birth. The second part, the specific or adaptive immune system, comprising T and B 
lymphocytes is, in comparison, much more specialized and ensues first after innate 
immunity has attempted to eliminate an infectious organism. Thus, the adaptive 
immune response takes longer to fully develop but is antigen-specific, meaning that it is 
focused in its effector functions against discrete parts of a microbe [5, 6]. I will in the 
following sections briefly outline the organization of these two systems primarily from 
an anti-microbial perspective.     
 
 
2.1.1 The innate immune system 
 
Innate immunity is divided into a cellular and a soluble arm, the former being 
comprised of specialized cells and the latter of serum factors such as complement and 
anti-microbial peptides. In addition, elements of innate immunity also include the 
natural barriers of our body such as the skin and the epithelium. These surfaces are in 
constant contact with the outside environment and therefore a primary route of 
infection for the pathogens that we encounter. Here, mucus membranes, lowered pH 
and secreted enzymes help protect the host against numerous attacks even before they 
are able to induce an immunological reaction [5, 6]. 
 
Monocytes/macrophages and granulocytes primarily combat invasive 
microorganisms through a process called phagocytosis in which the foreign invader is 
engulfed, killed and digested inside phagolysosomal granules containing toxic radicals 
and antimicrobial molecules [5]. Phagocytosis is enhanced by several classes of so 
called pattern-recognition receptors (PRRs) which help to facilitate the identification 
and uptake of invading bacteria. These receptors, categorized into either endocytic or 
signaling PRRs [7], identify key structural components that are either inherent to the 
pathogen itself or have been deposited there by other factors of the immune system. 
PRRs include, among others, scavenger receptors, mannose receptors and Toll-like 
receptors (TLRs). Upon activation, phagocytes also release soluble substances 
including cytokines, which not only work as effector molecules but also enable 
communication with other cells. Some of these are referred to as chemokines as they 
possess chemotactic activity and, when released, serve to recruit and guide other cells 
to sites of infection [5, 6]. Other soluble substances that are released by phagocytes are 
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included in the so-called respiratory burst of reactive oxygen species (ROS) and 
comprise superoxide anion, hydrogen peroxide and hypochlorous acid, all with potent 
microbicidal activity [6, 8]. Moreover, superoxide anion can also react with 
endogenously produced nitric oxide, giving rise to reactive nitrogen species (RNS) that 
complement the oxidative attack by ROS [9]. Macrophages and neutrophils are 
essential for withstanding infections and, due to their widespread location in tissues and 
swift recruitment, they are often the first to make contact with a foreign intruder [5].  
 
Dendritic cells (DCs), named for their characteristic cell membrane with protruding 
dendrites, are specialized in antigen uptake and have a very important function as 
antigen-presenting cells (APC) [10]. Antigen presentation is a key factor in T-cell 
stimulation, as T cells do not “see” antigens in their native form (e.g. an intact 
bacterium or a protein) but as short peptides bound to MHC (major histocompatibility 
complex) molecules on DCs or other cells with antigen-presenting capacity such as 
macrophages and B cells [11, 12]. Dendritic cells hereby fulfill an important link 
between innate and adaptive immunity, and being the only cells [10] that can properly 
activate naïve T cells they are often referred to as professional APCs. To accomplish 
their role, DCs effectively bind to, internalize and degrade a pathogen. Degradation 
takes place within the phagolysosome and results in the formation of short antigenic 
peptides which, in turn, bind to MHC molecules and become translocated to the cell 
surface. Here they are recognized by antigen-specific T cells through their receptors, 
which can recognize and bind foreign peptides only in the context of a peptide-MHC 
complex [13]. Like other members of the innate immune system, dendritic cells express 
numerous PRRs which facilitate the identification of pathogens and mediate cell 
activation. Thus, upon bacterial encounter and ligation of specialized PRRs, dendritic 
cells undergo a process of maturation that leads to increased antigen uptake, migration 
into the draining lymph node, upregulation of activating cell surface molecules and 
production of various cytokines, all essential for the peptide presentation and activation 
of T cells with the appropriate antigen specificity [14, 15].  
 
Natural-Killer (NK) cells are categorized as innate lymphoid cells (ILCs) of the innate 
immune system and constitute approximately 1-6% of circulating leukocytes in the 
peripheral blood [16, 17]. NK cells are especially critical in the early host response 
against viruses but are also important in immunity against certain classes of 
intracellular bacteria. NK cells target and destroy host cells which display altered 
features of “self”, notably down-regulated MHC class I molecules often induced by the 
pathological processes of viral infection and tumorigenesis. Killing is achieved not by 
phagocytosis but by release of cytotoxic proteins and proteases which permeate the 
target cell and induce osmotic cell lysis or programmed cell death (apoptosis) [5, 6].  
 
The complement system is central in the soluble arm of innate immunity and consists 
of a multitude of circulating proteins that can mediate the clearance of bacteria through 
three types of complement cascades: the classical, the alternative and the mannose-
binding lectin (MBL) pathways [18]. Initiation of these different pathways relies on the 
recognition of key structures found on surfaces of bacteria, either directly or through an 
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element which has been located there by other parts of the immune system. For 
example, the classical pathway is primarily activated by the recognition of antigen-
antibody complexes whereas the alternative and MBL pathways are initiated by direct 
complement binding to the bacterial membrane. All pathways eventually end in the 
formation of the membrane attack complex (MAC) which weakens the integrity of the 
cell membrane and induces bacterial lysis [19]. In addition, complement fragments 
deposited on the surface of bacteria also act as opsonins for receptors on neutrophils 
and macrophages facilitating the process of phagocytosis. Moreover, a number of 
cleaved fragments are referred to as anaphylatoxins and can mediate systemic effects 
by binding to specific receptors, influencing the blood flow controlled by localized 
smooth muscle and the release of inflammatory proteins from nearby mast cells [5]. 
Together, these factors help to intensify the inflammatory response by increasing the 
accumulation of fluids and cells recruited to the site of infection.     
 
All species resist bacterial invasion through the production of anti-microbial peptides 
(AMPs) [20]. These are short, soluble, amphipathic molecules with a broad range of 
anti-microbial effects including direct disruption of bacterial cell membranes, 
modulation of the inflammatory response and recruitment of phagocytes. AMPs are 
generally divided into defensins and cathelicidins and are produced by several different 
types of immune cells, including epithelial cells, macrophages and neutrophils [21]. 
Upon microbial infection, they are either quickly synthesized and released or cleaved 
from precursors stored in cellular granules [20].    
 
 
2.1.2 The adaptive immune system 
 
The adaptive immune system can be divided into a cellular and a humoral arm, 
mediated by T and B lymphocytes, respectively. Different from the innate immune 
system, T and B cells recognize pathogens in a much more specific manner and can 
through the generation of memory cells remember past insults by a previously defeated 
pathogen. More specifically, individual T cells and B cells exhibit specificity against a 
particular antigen by virtue of their individual T- and B-cell receptors, both of which 
are generated through a randomized form of gene rearrangement and unique for each 
single lymphocyte. Due to this process and the process of clonal expansion that is a 
result of antigen activation of naïve T or B cells, adaptive immune responses against a 
pathogen take longer to initiate and develop [5, 6].  
 
B cells and their secreted products, antibodies, constitute the humoral part of adaptive 
immunity. IgM, IgG, IgA and IgE antibodies are the secreted entities of the membrane 
expressed B-cell receptor and recognize a specific and defined part of an antigen (i.e. 
an epitope). Upon binding to its antigen, antibodies help to direct and focus the immune 
response; neutralizing the invader by direct blockage and/or promoting increased 
opsonization for elimination by other mechanisms of the immune system (e.g. 
complement activation, enhanced phagocytosis and antibody-dependent cellular 
cytotoxicity, ADCC). Although active against a variety of pathogens, humoral 
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immunity is believed to be particularly important in the protection against extracellular 
microbes [5].        
 
The effector arm referred to as cell-mediated immunity is comprised of several subsets 
of T cells with specialized functions. T cells are especially effective against 
intracellular pathogens such as viruses and certain classes of bacteria [5]. As mentioned 
above, the initial contact between antigen and an individual T cell is dependent on the 
presentation of the antigen on MHC class I and II molecules performed by APCs such 
as macrophages and dendritic cells. These cells patrol tissues armed to encounter 
pathogens, which then will be taken up and brought to secondary lymphoid organs 
where they will be presented to the T cells. The process of presentation divides T cells 
into two main classes depending on which MHC molecule on the APC that is engaged; 
the CD4+ T cells recognize peptides presented by MHC class II molecules, whereas 
CD8+ T cells recognize peptides presented by MHC class I [5]. Once activated, CD8+ T 
cells differentiate into cytotoxic T cells that kill infected target cells in a cognate, cell-
to-cell interaction [22]. Conversely, antigen primed CD4+ T cells expand and 
differentiate into various subsets of T-helper (Th) cells with a broad array of 
immunoregulatory functions. These subsets are defined primarily on the basis of the 
cytokines they produce and currently at least five distinct subsets have been defined 
(Table 1) [23]. The initial contact between an APC and the naïve CD4+ T cell is here 
supposed to play a crucial role in directing the T cell toward a specific Th-phenotype. 
Several APC and environmental signals, such as the nature of the antigen presented, 
cytokines secreted and co-stimulatory molecules engaged are integrated by the T cell 
and decide the final outcome of Th-development [24-26]. In a microbial setting, antigen 
presentation typically results in Th1 differentiation and has been shown to be dependent 
on the production of Interleukin (IL)-12 by the presenting APC [27]. Th1 cells, in turn, 
induce the propagation of inflammation suitable for eliminating bacteria by regulating 
macrophage activation and the production of special subclasses of antibodies by the B 
cells. In contrast, Th2 cells and the cytokines these cells produce (e.g. IL-4 and IL-13) 
promote B cells to secrete IgE and activate macrophages for an effective immune 
response against various types of extracellular parasites [5]. 
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2.1.3 Cytokines and chemokines 
 
As evident from above, the engagement and co-operation of both innate and adaptive 
immunity is often necessary in order to mount a response against a pathogen. The 
cellular communication that signifies these processes is to a large extent dictated by a 
group of proteins called cytokines. These chemical messengers, usually having a 
molecular weight between 10 and 30 kDa, regulate the initiation, duration and course of 
the immune response by binding to specific receptors on the surface membrane of cells. 
Their secretion is tightly controlled and they are typically present in very low 
concentrations (10-10 to 10-15 M). Once a particular cytokine has been secreted, it can 
either bind to receptors located on the secreting cell itself (i.e. autocrine production), 
receptors on nearby cells (paracrine production) or to receptors on cells located in distal 
parts of the body (endocrine production). Different cytokines generate different types of 
responses based on the modifications in gene expression induced by the cytokine 
receptors activated. Thus, a receptor-bound cytokine is able to influence the behavior of 
a target cell by activating or inhibiting basic functions such as activation, differentiation 
and/or proliferation [5, 6].  
 
The effects of cytokines are generally pleiotropic and may exhibit additive, synergistic 
or antagonistic features when secreted together. A level of redundancy exists in that 
many cytokines appear to fulfill very similar functions. Clearly, these features make it 
difficult to distinguish a precise role of a cytokine in a given situation but 
categorizations have still been made based on their structure, receptor specificity and 
function [6]. The latter usually encompasses a generalized division into pro-
inflammatory or anti-inflammatory [28]. Here, classical examples of pro-inflammatory 
cytokines include IFN-γ, TNF-α, IL-1β, IL-12p70 and IL-23, whereas IL-10, TGF-β 
and IL-1ra are considered as anti-inflammatory [29]. There are also cytokines such as 
IL-6 which have been demonstrated to play a role in both sides of this spectrum [30].  
 
The chemokines are a special subfamily of cytokines that regulate chemotaxis [6]. 
They control the migration of several leukocyte populations by binding to G-protein-
coupled receptors on the surface membrane of nearby target cells. The recruitment is 
guided by a concentration gradient that attracts cells to move in the direction of the 
chemokine-secreting source [31]. This is especially highlighted in situations of an 
encountered pathogen, where typically macrophages and/or neutrophils secrete 
chemokines in order to guide and recruit other immune cells to the site of infection. The 
chemokines are small with a molecular weight of only 7-12 kDa and are categorized 
into four families based on the position of conserved cysteine residues important in 
forming their 3-dimensional structure [32]. Some chemokines are considered pro-
inflammatory as they are primarily released in situations of infectious stimulation, 
while others are housekeeping chemokines, being constitutively produced and 
important in regulating migratory homeostasis and development [31]. Well-described 
chemokines especially related to this thesis include IL-8 (also known as CXCL8), MIP-
1β (CCL4) and MCP-1 (CCL2). 
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Research studying the properties of the different cytokines and chemokines has been 
greatly facilitated by the development of immunoassays using cytokine-specific 
monoclonal antibodies [33]. Methods such as the enzyme-linked immunosorbent assay 
(ELISA), enzyme-linked immunospot assay (ELISpot) and intracellular cytokine 
staining (ICS) in combination with flow cytometry has allowed investigators to gain 
insight into when and where different cytokines are produced and secreted. As implied 
by its name, ICS detects cytokines inside of cells, whereas both ELISA and ELISpot 
detect the cytokine after it has been secreted. This distinction is important in situations 
where production and secretion may be separately regulated by the activated cell. 
Moreover, while ELISA measures the amount of secreted cytokine in solution, ELISpot 
detects the frequency of cytokine-secreting cells within a population of cells [6]. 
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2.2 INNATE IMMUNITY SENSORS: A CALL TO ARMS 
 
 
While different with regard to their effector functions, innate and adaptive immunity 
are interlinked through an intricate and sophisticated network of co-operation. Here, the 
ancient building blocks of innate immunity have formed the support structures 
necessary for the evolution of the more advanced adaptive immune system. Thus, the 
inflammatory response, originating from within the innate immune system and used for 
shaping the most appropriate antigen-specific response, has in retrospect been catered 
to guide and influence the pathways taken by the adaptive immune system [34]. How 
innate immunity in this way “sense” its environment and mounts a rapid response based 
on cytokine release, conveying the nature of the pathogen encountered, was for many 
years unknown to immunologists [35].  
 
A theory of inherited receptors as a way of communicating this information was 
described in 1989 by Charles Janeway [36]. With brilliant insight, Janeway argued that, 
due to the heterogeneity and randomness of receptors generated in adaptive immunity, 
B and T cells would be unsuitable for the initial recognition of self versus non-self. 
Instead, he proposed that cells within the innate immune system, expressing receptors 
with a much broader type of pattern recognition would be better suited for this initial 
contact. Once triggered, they could serve not only as a first line of defense but also as 
instructors to the adaptive immune system. The first hints of the existence and nature of 
these special types of receptors were provided in 1996, when Jules Hoffman discovered 
how the gene “Toll” controlled the antifungal immune response in fruit-flies [37]. The 
year afterwards, Janeway himself identified a human homologue of Toll which 
controlled the activation of several cytokines and expression of co-stimulatory 
molecules in the monocytic cell line THP-1 [38]. Finally, in 1998, Bruce Beutler fully 
unlocked the relationship between a Toll receptor and its specific ligand when he 
demonstrated how mice unresponsive to lipopolysaccharide (LPS) had a point mutation 
in the Toll gene tlr4 rendering its function defective [3]. Consequently, mice were in 
the possession of a germ-line encoded receptor, which allowed them to recognize and 
respond to a major component derived from the cell wall of gram-negative bacteria. 
Without its proper functioning, mutant mice were overly susceptible to live infections 
using gram-negative bacteria but at the same time unscathed by a normally lethal 
injection of LPS [39].  These results highlighted the very important role in anti-
microbial immunity of this receptor which today is referred to as TLR4 [2]. Together, 
these discoveries have provided fundamental insights into the biology of innate 
immunity and how this is interlinked with the adaptive immune system.  
 
 
2.2.1 Signaling pattern-recognition receptors (PRRs) 
 
To date, several families of these “innate immunity sensors” or signaling PRRs have 
been identified. Apart from the Toll-like receptors (TLRs), they include C-type lectin 
receptors (CLRs), NOD-like receptors (NLRs) and the RIG-like receptors (RLRs) [40-
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42]. The PRRs can be expressed either at the cell membrane or intracellularly, ensuring 
detection of both intra- and extra-cellular pathogens (Figure 1). 
 
Figure 1. 
Simplified illustration describing the cellular localization of the different families of PRRs 
(TLRs, CLRs, NLRs and RLRs). Modified from [43].   
 
Typically, PRRs recognize and bind to structures on the pathogens, which have been 
conserved throughout evolution. Collectively, these motifs are called pathogen-
associated molecular patterns (PAMPs) and include diverse molecules such as lipids, 
carbohydrates and nucleic acids [40-42]. For example, RLRs and NLRs are both 
located in the cytoplasm were they recognize viral nucleic acids and bacterial 
peptidoglycans, respectively [44, 45], while CLRs are transmembrane receptors 
interacting with microbial carbohydrates [46]. Not only do PRRs bind and respond to 
PAMPs but a number of them have also been shown to recognize so called danger-
associated molecular patterns (DAMPs). These are endogenously produced molecules 
released by injured or necrotic cells [47]. Notably, degraded components of the 
extracellular matrix, certain heat-shock proteins and the nuclear factor high-mobility 
group box 1 protein (HMGB1) have all been classified as DAMPs capable of 
interacting with TLR4 [42]. Thus, in addition to its function as a receptor for LPS, 
TLR4 gives cells the ability to sense and react to an ongoing destruction of own host 
cells.  
 
The activation of PRRs leads to the triggering of a series of downstream intracellular 
signaling pathways which, in turn, control the transcription of inflammatory mediators, 
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including cytokines, modulators of PRR signaling as well as many uncharacterized 
proteins [40-42]. While activation of different PRRs can lead to the production of the 
same or a similar set of cytokines, the level of expression can be quite different even 
within the same family of PRRs [48]. In addition, variants of a particular ligand binding 
the same PRR may result in different levels of cytokine production, despite activating 
the same type of signaling pathway [49].  
 
 
2.2.2 The family of TLRs 
 
As detailed above, TLRs were the first family of PRRs discovered and subsequent 
studies have identified ten functional human receptors (TLR 1-10) in this family, many 
of which are expressed by monocytes and neutrophils [50, 51]. TLRs can be grouped 
depending on cellular location; TLR1, 2, 4, 5 and 6 are found on the surface of cells 
and primarily detect a variety of microbial membrane products such as peptidoglycan 
(PGN), lipoteichoic acid (LTA), LPS and flagellin (FLG). In contrast, TLR3, 7, 8 and 9 
are found inside of cells, more specifically in the membrane of endosomes where they 
primarily recognize viral and bacterial nucleic acids. TLR10 is expressed at the cell 
surface but its function is currently unknown [41]. All TLRs share a conserved 
structure involving an intracellular Toll/IL-1 receptor (TIR) signaling domain necessary 
for communicating TLR-activation to the nucleus and an extracellular, leucine rich 
repeats (LRRs) domain that gives the TLR its ability to bind specific ligands [40-42]. 
Upon PAMP ligation, TLRs are stabilized as dimers, forming a specific “m-shape” 
architecture that allows for the intracellular TIR domains to be properly aligned [41]. 
The dimerizing property of TLRs can in certain cases generate new binding abilities 
depending on the combination of TLR-receptors. For example, TLR2 can form 
heterodimers with either TLR1 or TLR6 to expand its repertoire of PAMP recognition 
to include not only peptidoglycan but also common bacterial derivatives such as 
lipoprotein (TLR1/TLR2) and LTA (TLR2/TLR6) [40-42]. In contrast, TLR4 
exclusively forms homodimers (TLR4/TLR4). These, however, associate with myeloid 
differentiation factor 2 (MD-2) and the LPS co-receptor CD14 [52] to form an LPS-
binding complex. In addition, a serum component, LBP (LPS-binding protein) 
facilitates the transfer of LPS molecules to the receptor complex and is thus an 
important component in LPS-signaling [53]. For LTA recognition, both CD14 and 
CD36 have been described as co-receptors in the activation of TLR2/TLR6 [54]. A 
summary of the current knowledge of human TLRs, their co-receptors and examples of 
their respective ligands is shown in Table 2. 
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2.2.3 Intracellular signaling following TLR-activation 
 
The activation of TLRs triggers specific types of signaling pathways and distinct 
cytokine responses [42]. These differences in activation are primarily explained by the 
recruitment of different adaptor molecules, i.e. myeloid differentiation primary 
response gene 88 (MyD88), TIR domain-containing adaptor inducing IFN-β (TRIF), 
TIR domain-containing adaptor protein (TIRAP) and TRIF-related adaptor molecule 
(TRAM), to the aligned TIR domains of each dimerized receptor. All TLRs, except 
TLR3, recruit and initiate MyD88 for further downstream signaling, and consequently 
this pathway is referred to as the MyD88-dependent pathway [42]. Intracellular 
signaling further relies on the recruitment of several IL-1 receptor-associated kinases 
(IRAKs) called IRAK4, IRAK1 and IRAK2 (Figure 2). 
 
Sequential activation of these proteins leads to the downstream interaction with TNF-
receptor-associated factor 6 (TRAF6), which in turn activates transforming-growth-
factor-β-activated kinase 1 (TAK1). TAK1 phosphorylates a complex composed of IκB 
kinase (IKK) α, IKKβ and nuclear factor κB essential modulator (NEMO). This 
complex releases the key transcription factor nuclear factor κB (NF-κB) by 
phosphorylating the inhibitory IκB proteins that limit its accessibility to the nucleus. In 
parallel, TAK1 also activates the mitogen-activated protein kinases (MAPKs), 
including extracellular-signal-regulated-kinase (ERK) 1, ERK2, p38 and c-jun N-
terminal kinase (JNK). Further downstream, MAPKs modulate translation and regulate 
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transcription factors such as activator protein (AP)-1, which together with the liberated 
NF-κB, lead to the up-regulation of pro-inflammatory cytokines and other TLR-
inducible genes [40-42].  
 
 
 
Figure 2. 
TLR-activation elicits the production of inflammatory cytokines and/or type I interferons 
through the Myd88- and/or TRIF-dependent pathways. Reprinted with permission from Oxford 
University Press [55]. 
 
 
In contrast to the MyD88-dependent pathway, TLR3 relies on the adaptor molecule 
TRIF for activation of the transcription factors NF-κB and IRF3. As a result, this 
activation pathway has been named the TRIF-dependent pathway. Here, the induction 
of cytokines and type I interferons has been shown to be especially important in anti-
viral immunity. Similar to the signaling pathway of MyD88, TRIF also recruits and 
activates TRAF6 and TAK1 for downstream activation of NF-κB. However, IRF3 is 
translocated into the nucleus following its phosphorylation by another set of proteins, 
involving the recruited signaling complex TANK-binding kinase 1 (TBK1) plus IKKε 
(also known as IKKi) together with TRAF3. TLR4 is unique in this setting as it 
activates both the MyD88- and TRIF-dependent pathways in a sequential order, first 
through the adaptor molecule TIRAP for MyD88-dependent activation, and then 
secondly, after the TLR4 receptor has been internalized into endosomes, the TRIF-
dependent pathway by a complex-formation with TRAM [40-42] (Figure 2). 
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2.2.4 Negative TLR-regulators 
 
While activation of TLRs is essential for the establishment of inflammation in response 
to invading microorganisms, the signaling of these receptors must also be tightly 
controlled in order to avoid chronic inflammation and excessive immune responses to 
pathogens [42]. Researchers have identified several negative regulators that affect 
signaling at multiple levels of the TLR-signal transduction pathways. These include, 
among others, Toll-interacting protein (TOLLIP), MyD88 short (MyD88s), IRAK-M, 
suppressor of cytokine signaling (SOCS)-1, A20, SHIP-1, sterile-α and Armadillo 
motif containing proteins (SARM) and suppressor of IκBε (SIKE) [56-58]. These 
proteins exert their inhibitory effects in different ways. For example, TOLLIP inhibits 
TLR2 and TLR4 by sequestering IRAK1, thereby resulting in impairment of NF-κB 
activation. MyD88s works by forming heterodimers with the full length MyD88, 
impeding the natural phosphorylation of IRAK1 by IRAK4. Similarly, the alternative 
kinase IRAK-M associates with IRAK4 and has been reported to disrupt the assembly 
of MyD88-IRAK4-IRAK1 complexes, thereby preventing the downstream activation 
of TRAF6. SOCS1 is member of a family of proteins with important roles in 
suppressing cytokine signaling. In relation to TLR4, mouse macrophages lacking 
SOCS1 show increased production of pro-inflammatory cytokines and nitric oxide in 
response to LPS. This lack of inhibition is suggested to stem from the ability of 
SOCS1, an E3-ubiquitin ligase, to target TIRAP for protein degradation. A20 lowers 
LPS-activation by negatively influencing the activation of TRAF6, whereas SHIP-1 
interferes with the normal activity of TBK1. SARM, an alternative adaptor molecule, is 
specifically involved in down-regulating TRIF-dependent TLR-signaling. Likewise, 
SIKE has been found to impede IRF3 activation [56-58]. Together, these proteins 
obviously exert a complex influence on the final outcome of TLR-induced gene 
expression. This is especially highlighted by the well-studied phenomenon called 
endotoxin tolerance whereby monocytes subjected to an initial dose of LPS become 
refractory and fail to produce pro-inflammatory cytokines in response to a secondary 
challenge with LPS [59]. Here, the downturn in production of cytokines has in part 
been explained by the late up-regulation of several negative TLR-regulators following 
the first LPS challenge [60]. Thus, the induced gene expression will change and be 
modified as the TLR4 response progresses from an initial phase dominated by pro-
inflammatory mediators to a secondary, LPS-tolerant phase characterized by anti-
inflammatory cytokines and proteins such as TOLLIP, IRAK-M, SHIP-1, SOCS1, 
SARM and SIKE [56-58]. Finally, endotoxin tolerance has also been linked to the 
induction of so-called microRNAs [61]. These are small RNA molecules, induced e.g. 
after LPS-activation, that downregulate gene-expression at the post-transcriptional level 
by binding to the transcribed mRNA of certain genes. Over 700 microRNAs have been 
identified within the human genome, and of these, seven have been linked to the 
regulation of the TLR4 signaling pathway [62]. Here, the most well studied example is 
the microRNA called miR-146a that downregulates TNF-α production by binding to 
the mRNA of TRAF6 and IRAK-1. By transfecting miR-146a into unstimulated THP-1 
cells, a phenomenon resembling LPS tolerance is artificially induced [63].  
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2.3 MONOCYTES, MACROPHAGES, NEUTROPHILS AND THE 
INFLAMMATORY RESPONSE 
 
Inflammation arises through a complex cascade of serological and cellular events 
following injury or infection. During this evolutionary well-conserved process, the 
immune system is mobilized, the harmful stimuli eliminated and processes initiated that 
result in the repair of damaged tissues [64]. Inflammation can in many cases be 
recognized due to the tell-tale signs in afflicted sites of the body including swelling, 
redness, heat and pain, all manifestations of the immune system’s attempt at combating 
the injurious stimuli and bringing back the tissue to its original homoeostatic state [6]. 
Inflammation is often described as a double-edged sword; beneficial and protective, but 
also the cause of tissue damage as an unavoidable part of its engagement. Vital to the 
initiation, propagation and final outcome of this process are monocytes/macrophages 
and the PRR-inducible cytokines that they command [65, 66].     
 
Monocytes originate from lineage-committed hematopoietic stem cells in the bone 
marrow and constitute around 4-10% of leukocytes in human blood [11]. After 
approximately 3 days in circulation as non-proliferating cells, monocytes migrate 
across the endothelium and differentiate not only into tissue-specific macrophages or 
monocyte-derived dendritic cells but, depending on the environmental signals, also to 
other cell types including microglia cells and osteoclasts [67]. Thus, monocytes can be 
looked upon as transitional cells serving to replenish these tissue cell populations when 
required. Upon injury or infection, the recruitment of monocytes from bone marrow is 
increased with a large number of these cells migrating toward the inflamed tissue [68]. 
 
Monocytes and macrophages are ubiquitous throughout the animal kingdom being 
found in mammals, amphibians and fish. In fact, macrophage-like cells are also present 
in insects and simple multicellular organisms [11]. Apart from their fundamental role as 
surveillance cells, safeguarding us from infection, monocytes and macrophages also 
help the body to regulate various homeostatic functions like the clearance of apoptotic 
cells, removal of toxic compounds and tissue remodeling. In addition, through their role 
as APCs, monocytes/macrophages constitute accessory cells for the induction of 
antigen-specific immune responses [11]. Together, macrophages, dendritic cells, 
monocytes and their progenitors in the bone marrow form a network of cells called the 
mononuclear phagocyte system (MPS) [69, 70]. This network is represented in virtually 
all tissues of our bodies and is an important source of TLR-induced cytokines in the 
development of the inflammatory response [65]. 
 
 
2.3.1 Initiation of the inflammatory response 
 
As described in the background section, tissue-residing macrophages are often the cells 
making the first contact with an invading pathogen [64]. This encounter will normally 
result in the phagocytosis of the pathogen and the activation of TLRs through binding 
of PAMPS like LPS or LTA. This, in turn, leads to the induction and secretion of pro-
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inflammatory cytokines and chemokines like IL-6, IL-8, MIP-1β, TNF-α and IL-1β 
[71] which induce a wide range of secondary effects on nearby cells and tissues 
including up-regulation by the endothelium of adhesion molecules such as selectins and 
the intercellular adhesion molecule 1 (ICAM-1). Furthermore, the cytokines also 
increase vascular permeability leading to the typical swelling and redness associated 
with inflammation and, if they reach the blood, production of acute-phase proteins by 
the liver. Examples of these include mannan-binding lectin (MBL) and C-reactive 
protein (CRP) both of which can bind bacterial structures and form complexes that 
trigger complement activation. In addition, IL-6, TNF-α and IL-1β are all known as 
endogenous pyrogens as they induce fever by affecting the hypothalamus in the brain 
[5, 6].  
 
In response to the initial “call to arms”, circulating neutrophils and monocytes 
extravasate from the bloodstream guided by the concentration of chemotactic signals 
and adhere to the vessel wall in areas of activated endothelial cells [6]. The essential 
steps of this process are similar for neutrophils and monocytes involving rolling, 
activation, endothelial arrest and transendothelial migration (Figure 3) [72].  
 
 
Figure 3. 
Illustration of neutrophil extravasation showing the main receptor-ligand interactions between 
leukocyte and endothelium that allow for transendothelial migration into tissues. The essential 
steps of rolling, activation, endothelial arrest and transendothelial migration is similar for 
monocytes but involves different combinations of receptors and chemotactic factors as 
indicated. Adapted from [6]. 
 
 
Neutrophils begin rolling by binding to E- and P-selectins on the endothelium through 
their expression of L-selectin (CD62L) and P-selectin glycoprotein ligand-1 (PSGL-1) 
[73]. These receptor-ligand interactions slow down cellular movement along the area of 
inflamed endothelium and permit chemokines such as IL-8 and MIP-1β to bind to 
receptors on the neutrophils and induce conformational changes in their integrin 
molecules LFA-1 (CD11a/CD18 or Lymphocyte function-associated antigen 1) and 
MAC-1 (CD11b/CD18 or Macrophage-1 antigen) [74]. These changes strengthen the 
neutrophil affinity for ICAM-1 and lead to complete endothelial arrest. Finally, 
transendothelial migration allows neutrophils to migrate into tissues. Here, 
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chemoattractants such as bacteria-derived peptides and components of the complement 
cascade serve as additional signals to IL-8 and MIP-1β for the movement of neutrophils 
towards the site of infection [6]. Monocytes rely on a very similar sequence of events 
using CD62L to start rolling. However, their integrin molecules also include very late 
antigen 4 (VLA-4) that binds to vascular cell adhesion molecule 1 (VCAM-1) on the 
activated endothelial cells [73]. Moreover, integrin activation in monocytes occurs 
primarily through the binding of MCP-1 (CCL2) [6].  
 
When neutrophils arrive at the site of infection, they instantly attack the intruder 
through the process of phagocytosis, the production of ROS/RNS and the release of 
granules containing an array of antimicrobial substances and proteolytic enzymes [75]. 
Neutrophil granules are divided into primary, secondary and tertiary granules which 
release their content in hierarchal order beginning already during the process of 
transendothelial migration [76]. Here, the tertiary granules, containing extracellular 
matrix degrading enzymes, help the neutrophil to extravasate. Then, at the site of 
infection, the contents of the secondary and primary granules are released, either 
extracellularly or inside the neutrophil through the membrane of internalized 
phagocytic vacuoles. The secondary and primary granules are “loaded” with acid 
hydrolases and antimicrobial substances, including the human neutrophil peptides 1-3 
(HNP 1-3), heparin binding protein (HBP), myeloperoxidase (MPO), LL-37, and 
members of the serine protease family like cathepsin and elastase [76, 77]. Apart from 
the direct role of these granule proteins in eradicating bacteria, a growing body of 
research has demonstrated that many of these components also possess 
immunoregulatory capacity. For example, the antimicrobial peptides LL-37, HBP and 
HNP1/2 have all been shown to have chemotactic effects and can induce cytokine 
production in a range of other immune cells, including monocytes and dendritic cells 
[78-80].  
 
Neutrophils reportedly express most members of the TLR family, except for TLR3 and 
TLR7 [51]. Consequently, many bacteria-derived PAMPs, will be able to stimulate 
neutrophils and induce the secretion of cytokines and chemokines [81]. Apart from a 
well-established production of IL-8, MIP-1β and IL-1ra following LPS-stimulation in 
vitro, several studies have reported on neutrophils secreting a wide range of both 
inflammatory (IL-6, TNF-α, IL-1β, IL-12p40) and anti-inflammatory (IL-10) cytokines 
[82-85]. However, other investigators have questioned this and have attributed the 
detection of several of these cytokines to the presence of contaminating monocytes [86, 
87]. Nevertheless and irrespective of their true cytokine profile, the proven production 
of IL-8 and MIP-1β, demonstrates that neutrophils not only display microbicidal 
activity but that they can also communicate with other immune cells via chemotactic 
factors and recruit these to the site of infection [88].   
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2.3.2 Activation of the coagulation system 
 
Inflammation in response to infection also affects the coagulation system. Bacterial-
derived LPS and cytokines produced by monocytes/macrophages promote the 
intravascular deposition of fibrin in the immediate vicinity of inflamed tissues and 
prevent spreading of pathogens from the site of infection by forming a physical barrier 
or clot [89]. This process relies upon the interaction between a molecule called tissue-
factor (TF) and the coagulation factor VIIa in plasma. TF is a membrane-expressed 
protein found constitutively in subcutaneous tissues but is also up-regulated on the cell 
surface of monocytes and endothelial cells in response to cytokines such as IL-6 [90]. 
The formation of an activated complex between tissue-factor and factor VIIa (TF-
FVIIa) catalyzes the conversion of the plasma enzymes factor IX and X, which trough a 
sequence of activation cascades, leads to the generation of thrombin and the subsequent 
conversion of circulating fibrinogen into fibrin [89, 91]. Activated platelets increase the 
efficiency of this process by bringing certain components of the coagulation cascade in 
close proximity at their phospholipid-containing surfaces. In addition, plasma and 
platelet derived factor XIIIa, cross-links the strands of converted fibrin thereby 
stabilizing the clot generated [92].  
 
 
2.3.3 Macrophage differentiation   
 
Once monocytes have migrated into the infected tissue, they differentiate into 
macrophages or monocyte-derived dendritic cells [93]. Here, cues in the 
microenvironment, including PAMPs, DAMPs, cytokines and cognate interactions are 
believed to influence and dictate their differentiation into various macrophage 
phenotypes suited for the particular type of pathogen and tissue [94]. In humans, two 
well established macrophage phenotypes have been described; the classically activated 
macrophages, designated as M1, and the alternatively activated macrophages 
designated as M2 [95]. In the case of an acute bacterial infection, the classical M1 
phenotype is favored over M2 due to the differentiating signals of NK-cell derived 
IFN-γ and microbial PAMPs. These two stimuli are critical for M1 polarization and 
give rise to macrophages that are specially adapted to kill microbes by virtue of their 
enhanced production of pro-inflammatory cytokines/chemokines, increased antigen-
presenting capacity (upregulation of MHC class II, CD80, CD86) and heightened 
production of ROS/RNS [96, 97]. In addition, these inflammatory macrophages can 
also produce IL-12p70 and IL-23 which promote the differentiation of Th1 and Th17 
responses, respectively [98]. In contrast, the alternatively activated macrophages are 
better equipped to fight extracellular parasites and to promote wound healing and are 
considered as being mainly anti-inflammatory in their nature. M2 macrophages have 
been further subdivided into M2a, M2b and M2c depending on differences in their 
phenotype and the signature mediators which elicit their development in vitro (Figure 
4) [71, 99]. For example, the M2a macrophages are induced in response to IL-4 or IL-
13 and secrete many immunoregulatory cytokines such as IL-10, IL-1ra and 
chemokines (CCL17/18/22/24). In addition, they express characteristic receptors such 
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as the mannose and scavenger receptors. M2b macrophages develop in response to a 
combination of immune complexes and TLR-agonists, forming IL-10 producing 
macrophages with concomitant secretion of pro-inflammatory cytokines and expression 
of co-stimulatory molecules (CD80, CD86). Finally, the M2c phenotype is found after 
exposure to IL-10, TGF-β or glucocorticoid hormones. Similar to M2a, they express the 
mannose and scavenger receptors and, in addition to IL-10 and IL-1ra, they also 
produce TGF-β [71]. While these phenotypes have been used as a framework by which 
the heterogeneity of macrophages has been outlined, it is also clear that they only 
partially represent the full complexity of these cells both in vitro and in vivo [94]. 
Exceptions to the different polarization states are frequently found and in mice a more 
flexible classification has been suggested where the different macrophage functions 
(inflammatory, wound healing and regulatory) have been described as a continuum of 
blended phenotypes within a color wheel [98]. For simplistic reasons, I will in the 
following parts of this thesis refer to the various phenotypes of M2a, M2b and M2c as 
the alternatively or M2 activated macrophages. 
 
 
 
Figure 4. 
The phenotype and cytokine producing capabilities of macrophages polarized into M1, M2a, 
M2b and M2c. Modified from [71]. 
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2.3.4 Macrophage plasticity and the resolution of inflammation 
 
In contrast to T cells, which give rise to several subsets through somewhat stable 
epigenetic changes in gene expression [100], macrophages are known to display a high 
degree of plasticity being able to switch back and forth between opposing phenotypes 
given the proper set of differentiation signals [98, 101]. For example, M2 macrophages 
can be pushed towards an M1 phenotype through exposure to recombinant IFN-γ [102, 
103] and identically differentiated macrophages may respond differently to the same 
stimuli when placed in new or alternative environmental settings [94]. This form of 
cellular “adjustability” is also apparent in response to PRR-activation, where the genes 
expressed early after LPS stimulation differ significantly from those expressed at a later 
stage [104]. In addition, macrophages commonly revert back to a basal phenotype when 
left unstimulated after a period of cytokine exposure. For example, in vitro 
differentiation of macrophages into immature dendritic cells using the cytokines IL-4 
and GM-CSF can essentially be reversed following the continued culturing of these 
cells for a few days in the absence of any cytokines [105]. In line with this, macrophage 
phenotype and function will change as the inflammatory response progresses, giving 
rise to a population of cells that from an outside perspective is confusingly 
heterogeneous; the emergence of pro-inflammatory M1 macrophages adapted to killing 
microbes is followed, through a transition, by various subsets of M2 cells suited to 
bring down inflammation and reestablish tissue homeostasis [94, 106, 107].   
 
The exact mechanisms mediating this phenotypic shift are currently incompletely 
understood [98, 107, 108]. However, in the context of invading microorganisms, the 
cues in the microenvironment will certainly change as the clash between cellular 
immunity and the offending pathogen progresses and finally resolves. A natural decline 
in microbial products coupled with an accumulation of late warfare material like 
apoptotic neutrophils, anti-inflammatory cytokines and metabolites are believed to be 
critical in the conversion of M1 macrophages into M2. For example, following 
complete bacterial clearance, apoptotic neutrophils are removed by macrophages 
through phagocytosis. This process, called efferocytosis, naturally hinders the 
extracellular release of neutrophil derived DAMPs but the activity itself also leads to a 
shift towards M2 macrophages through the induced secretion of TGF-β [108]. 
Moreover, the natural progression of LPS-stimulated M1 macrophages from an early 
pro-inflammatory phase to a later, IL-10 secretory phase, dampens inflammation and 
promotes alternative differentiation in an autocrine/paracrine fashion [104]. In addition, 
production of IL-4 by basophils, mast cells and recruited Th2-cells may further 
strengthen the shift from classical to alternative macrophage activation [94, 98]. 
Naturally, these changes in the macrophage population are not necessarily limited to 
the active reprogramming of individual M1 cells into M2. Transitions in overall 
phenotype can also be a result of newly recruited monocytes encountering a changed 
microenvironment of the inflamed tissue, leading to a higher proportion of M2.  
 
Thus, the buildup of M2 macrophages that occurs in the later stages of the 
inflammatory response is believed to be a prerequisite for inflammation to resolve and 
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for the promotion of wound healing [108]. By predominantly secreting high levels of 
anti-inflammatory cytokines such as IL-10 and IL-1ra, M2 macrophages down-regulate 
the release of pro-inflammatory mediators from surrounding cells and tissues [71]. 
Further, they effectively phagocytose dead cells, necrotic tissues and degraded 
components of the extracellular matrix, factors that would otherwise promote continued 
M1 differentiation by acting as DAMPs [42, 47]. In addition, M2-related production of 
TGF-β and platelet-derived growth factor (PDGF) stimulates the differentiation and 
proliferation of fibroblasts into myofibroblasts which, in turn, synthesize collagen and 
regenerate the extracellular matrix, both important for restoring tissues and regaining 
homeostasis [106]. Moreover, M2 macrophages also produce various other factors such 
as vascular endothelial growth factor (VEGF) and special types of chemokines that 
recruit regulatory T cells. Finally, M2 macrophages help repair destroyed tissues by 
secreting products that regulate important metabolic functions [106, 108]. Once 
inflammation has subsided and tissues have been healed, macrophages either undergo 
apoptosis or leave the site through the lymphatics [109].   
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2.4 MONOCYTE HETEROGENEITY 
 
Given the diversity of macrophages and the wide range of activities these cells engage 
in during both homeostasis and infection, it has also been natural to look at monocytes 
not just as a pool of precursor cells for macrophages but as cells with their own level of 
heterogeneity and distinct effector functions [110]. Indeed, already at the 
morphological level monocytes show variations in both size and nuclear appearance. 
During the 1980s, differences in density were used for dividing monocytes into a 
dominant population of large monocytes and a corresponding minor population of 
small monocytes [11]. By using flow cytometry, Ziegler-Heitbrock and colleagues 
demonstrated in 1988 that the population of small monocytes could be distinguished 
from other monocytes based on their expression of the Fcγ-III receptor, CD16 [111]. 
Conversely, the dominant population of large monocytes was CD16 negative but 
expressed significantly higher levels of the surface marker CD14 [112]. Thus, based on 
these two markers, monocytes could be divided into two subsets defined as the classical 
CD14highCD16- subpopulation, comprising 85-95% of total monocytes, and the 
CD14lowCD16+ subpopulation making up the remaining 5-15% of cells [11].   
 
In the following decades, much work was focused on identifying the immunological 
and functional features of these two monocyte subsets and several investigators found 
differences in their expression of cell surface markers connected to cell trafficking and 
chemotaxis [113]. For example, CD16+ monocytes were found to have a high 
expression of CX3CR1 and low expression of CCR2 and they migrated in response to 
the chemokine CX3CL1 [114, 115]. By contrast, the classical monocytes displayed 
significant expression of CCR2 and CD62L, but little or no CX3CR1 and migrated in 
response to CCL2 [116, 117]. These variations in cell surface markers and behavior 
suggested a possible tissue-specific surveillance and that the extravasation of each 
subpopulation might be regulated by alternative scenarios of inflammation [118]. 
Moreover, CD16+ monocytes were identified as primarily pro-inflammatory due to 
their high production of TNF-α and low production of IL-10 in response to LPS [119, 
120]. Compared to the classical subset, CD16+ monocytes were also considered as 
more differentiated and macrophage-like [121] and increased in numbers during 
various inflammatory conditions [122-124]. They also displayed higher antigen 
presenting capacity [125] and in an in vitro model of transendothelial migration they 
were seen to develop into dendritic cells [126]. As a consequence, CD16+ monocytes 
were hypothesized to have a unique role in innate immunity. 
 
 
2.4.1 Three monocyte subsets and their production of cytokines 
 
While the division of monocytes into two subsets was the standard for a long time, it 
eventually became apparent that further diversity existed within the CD16+ 
subpopulation [114, 127, 128]. Based on the same defining markers of CD14 and 
CD16, the CD16+ monocytes could thus be separated into two subsets of 
CD14highCD16+ and CD14lowCD16++. This additional level of monocyte heterogeneity 
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was in 2010 incorporated in the official nomenclature of human monocytes, now 
dividing them into three major subpopulations: the classical (CD14highCD16-), the 
intermediate (CD14highCD16+) and the non-classical (CD14lowCD16++) monocytes 
[129]. While this definition of a third subset has not rendered previous reports on 
monocyte heterogeneity invalid, it has on the other hand raised questions as to how 
earlier features ascribed to the whole population of CD16+ monocytes should be 
separated between the intermediate and non-classical subsets [130].  
 
In order to further elucidate these questions, a number of studies have recently 
reevaluated monocyte heterogeneity taking into account all defining subsets and using 
several cell surface markers, gene expression analysis and TLR-induced cytokine 
production assays [127, 131, 132]. Due to the fact that the classical subset has remained 
intact in this new paradigm, much of the data from earlier studies have been reproduced 
and for instance, classical monocytes are still distinguishable from other monocytes by 
their high expression of CCR2 and CD62L. However, for the intermediate and non-
classical monocytes, further phenotypic differences have been demonstrated as 
exemplified by a lower expression of CX3CR1, comparably higher expression of CCR5 
and more significant levels of cell surface markers connected to antigen presentation in 
the intermediate subpopulation [127, 132, 133]. With regard to cell surface markers, 
intermediate monocytes appear to be wedged between the classical and non-classical 
monocytes, suggesting that they may represent a transitional stage between these two 
subpopulations [127, 132]. The notion that the three subsets represent a continuum of 
differentiation with the intermediate monocytes being the “gradual link” between the 
other two has been corroborated by results from gene expression analysis [132] and in 
the treatment of patients using recombinant M-CSF, where an initial rise in the classical 
subpopulation of monocytes is followed sequentially by increases in intermediate and 
finally the non-classical subset [134]. In addition, purified preparations of classical 
monocytes that are kept in culture spontaneously acquire attributes of intermediate and 
non-classical monocytes while simultaneously down-regulating markers associated 
with their original classical phenotype [132, 133, 135]. However, despite this type of 
circumstantial evidence, there is still a possibility that monocyte heterogeneity 
represents an early commitment by progenitors in the bone marrow and that tissue 
specific or inflammatory signals account for the recruitment of these different 
populations and for their varying numbers in peripheral blood [11]. 
 
Although the differential expression of surface markers has been critical for the 
recognition and definition of different monocyte subsets, cytokine production is 
supposedly an important function of these cells in vivo. Diversity in this regard has 
usually been evaluated in vitro through TLR-ligation and determinations of the 
cytokine profile of monocyte subsets isolated by flow cytometric cell sorting [127, 131, 
132]. However, in contrast to the relative consensus regarding their expression of cell 
surface antigens, studies of cytokine profiles in the different monocyte subsets have 
generated conflicting results. For example, Cros et al found intermediate monocytes to 
be the main producers of IL-6, TNF-α and IL-1β in response to LPS whereas the non-
classical monocytes were described as poor LPS-responders [131]. Instead non-
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classical monocytes preferentially secreted high levels of pro-inflammatory cytokines 
in response to TLR7/8-ligation, possibly indicating a special role of this subset in the 
immunity against viruses. However, these results do not correspond to those of 
Skrzeczynska-Moncznik et al, who a few years earlier had identified the non-classical 
monocytes as not only capable of responding to LPS but also being the main producers 
of TNF-α [127]. In addition, the intermediate monocytes were here defined as the main 
producers of IL-10 and not the classical subpopulation as suggested by Cros et al. In 
2011, Wong et al described yet another relationship for the cytokine secreting profiles 
of the three monocyte subsets. Using a virtually identical experimental setup 
stimulating the different monocyte subsets with increasing doses of LPS, the 
intermediate monocytes were here distinguished as the cells with the lowest production 
of IL-6, TNF-α and IL-1β [132]. Moreover, the non-classical monocytes responded 
very well to LPS and were defined as the subset producing the highest levels of IL-1β 
and TNF-α. In addition, the classical monocytes were recognized for having the 
broadest range of cytokine secreting capacity overall, producing high to moderate 
levels of all cytokines tested. A summary of these findings is found in Table 3. 
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2.4.2 Methodological considerations 
 
The apparent inconsistencies between studies investigating the same cytokines, in spite 
of using similar experimental approaches and conditions, have been suggested to stem 
from minor differences in the methods employed [132]. This appears likely considering 
that monocytes are easily influenced by differences in in vitro handling [11]. For 
instance, some of the anti-CD14 antibodies that are commonly used to isolate 
monocytes have been reported to attenuate LPS responses by disturbing the function of 
CD14 as an essential co-receptor in the activation of TLR4 [136]. As other anti-CD14 
antibodies have been claimed not to affect LPS activation, this may well explain many 
of the inconsistencies in cytokine levels reported by different investigators [137, 138]. 
Furthermore, when using flow cytometry, the gating process is both critical and 
difficult especially when considering that the current definition of monocyte 
subpopulations relies on relatively minor differences in the expression of CD14 and 
CD16. Thus, while the intermediate and non-classical monocytes are supposed to be 
distinguished by variable levels of CD16 expression (CD16+ versus CD16++) this 
difference is not taken into full account by all groups when subpopulations are acquired 
[127, 133]. Finally, cytokine determinations have mostly been performed using ELISA 
or Luminex assays. While both are sensitive techniques, they are also susceptible to the 
interference by soluble cytokine receptors and the uptake of cytokines by receptor-
bearing cells in the cultures. Such “consumption” of released cytokines has been 
reported previously for T-cell cytokines and is likely to represent an important factor in 
the investigation of monocyte-derived cytokines as well [139]. The level of cytokine 
consumption is, in turn, affected by a number of factors such as the composition of 
cells and the extent of cellular contact during the culture, the propensity of each 
monocyte subset to “consume” cytokines as well as the ability of the antibody pairs that 
are used in the assay, to recognize free cytokine contra the same cytokine bound to 
soluble receptors. Thus, reported levels of TLR-induced cytokines produced by 
classical, intermediate and non-classical monocytes may not necessarily reflect their 
individual ability to synthesize and release these mediators.  
 
Due to the unique properties of the ELISpot/FluoroSpot assays, used in this study, 
many of these interfering factors can be reduced or eliminated. Thus, in both assays, the 
cytokine is captured close to its source of release, which minimizes its binding to 
receptors on neighboring cells and the risk of interference by soluble receptors.   
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2.5 THE PATHOPHYSIOLOGY OF SEPSIS 
 
The events of the inflammatory response described in earlier sections of this thesis are 
under normal circumstances beneficial to the host as they promote local coagulation 
and confinement of pathogens to the site of infection [140]. Here, the destructive 
powers of infiltrating monocytes and neutrophils can be insulated and channeled 
towards eradicating the intruder while simultaneously limiting self-inflicted damages to 
a compartmentalized part of the host [64]. However, in rare instances, the systemic 
response against a disseminated bacterial infection becomes dysregulated [141] and 
extends beyond the barriers of a beneficial containment. The result is a widespread 
TLR-activation of innate immune cells and the initiation of the so-called systemic 
inflammatory response syndrome (SIRS). During this hyperinflammatory phase, 
cytokines like TNF-α, IL-1β, IL-6, IL-8 and IFN-γ are excessively released from 
several cellular sources including monocytes/macrophages, neutrophils, lymphocytes 
and endothelial cells. These mediators promote increased activity of several important 
effector functions like cellular activation, recruitment, extravasation and degranulation. 
For example, IFN-γ induces enhanced cytokine production by monocytes/macrophages, 
whereas TNF-α and IL-1β prime neutrophils for increased production of ROS and nitric 
oxide. Simultaneously, soluble elements of the innate immune system become 
activated, leading to a powerful increase in the complement split products C5a and C3a. 
These anaphylatoxins, in turn, induce chemotaxis and cause systemic effects by binding 
to specific receptors on mast cells. Elevated levels of HMGB1 follow this initial phase, 
exacerbating various aspects of inflammation by acting as a DAMP and forming 
synergistic, immunomodulating complexes with other cytokines [142, 143]. Depending 
on the overall severity of this response, it can lead to profound vascular dilatation, 
capillary leak, cell death, tissue injury and organ dysfunction [144-147]. Put in other 
words, many of the cells and factors that give rise to the signs of inflammation 
(swelling, redness, heat and pain) under normal, compartmentalized conditions are 
suddenly unleashed systemically, leading to an exaggerated and dysregulated response 
[148-150]. In this situation it is the exaggerated response and not the bacteria 
themselves, that becomes the primary threat to the host [151].  
 
The current clinical criteria for patients suffering from SIRS were established in 1992 
[152] and include two or more of the following 4 symptoms or signs:  
 
- Body temperature below 36°C or higher than 38°C. 
- Heart rate above 90 beats per minute. 
- Respiratory rate higher than 20 breaths per minute or an arterial partial pressure 
of carbon dioxide less than 4.3 kPa. 
- In the blood: Leukocytes <4000 cells/mm3 or >12000 cells/mm3 or >10% 
immature neutrophils.   
 
When SIRS is induced by a known or suspected infection, this is defined as sepsis 
[152]. Severe sepsis occurs when the inflammatory cascade of sepsis progresses and 
gives rise to organ dysfunction not associated with the original septic focus or due to an 
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underlying chronic disease. Finally, septic shock is the outmost dangerous state and is a 
term used for patients who, in addition to symptoms of severe sepsis, also display an 
abnormally low blood pressure despite being given adequate fluid resuscitation [147, 
153]. Overall, the mortality rate of sepsis is high, ranging from 18-50% depending on 
stage of sepsis and study cited [154-156]. In one recent review comprising more than 
11000 patients diagnosed with severe sepsis upon inclusion, a substantial proportion 
(49.7%) died before the study was completed [147]. Among the study participants, 
gram-negative and gram-positive bacteria accounted for 57% and 44% of confirmed 
infections respectively, whereas fungi were found as the causative agent in 11% of 
infections. As indicated by the figures several patients suffered from multiple 
infections. The lung (47%) followed by the abdomen (23%) and the urinary tract (8%) 
were the most common primary sites of infection. In general, the incidence of sepsis is 
increasing due to an aging population, increased use of immunosuppressive medicine, 
and more patients undergoing complicated surgery [144].  
 
On the molecular level, the identification of PRRs has generated much insight into how 
the immune system reacts and how cytokine responses are initiated by infection [35]. 
However, the exact mechanisms that give rise to the “inappropriate” host response in 
the beginning of the septic process are still poorly understood [141]. Yet, as touched 
upon above, the aggressiveness of the bacterium, the size of the inoculum and the 
immune competence of the affected individual are all known to influence the outcome 
[151]. Moreover, since the onset of sepsis primarily involves cells belonging to the 
innate immune system, genetic predisposition in TLRs is likely to be a significant 
factor [157]. Indeed, studies of identical twins have demonstrated a significant 
contribution of genetics in the likelihood of dying from an infectious disease [158] and 
deficiencies in TLR-signaling are associated with increased susceptibility to acquire 
sepsis [159, 160]. 
 
 
2.5.1 Role of monocytes in sepsis 
 
Due to sepsis being recognized as a systemic disease where cells in the circulation are 
supposed to propagate the spreading of an uncontrollable inflammation, monocytes 
have long been on the “list of suspects” when trying to explain the underlying 
pathophysiology [161, 162]. Monocytes express high levels of most TLRs [50] and 
TLR-activated monocytes in vitro are the main producers [163] of the cytokines that 
are typically found at elevated levels in the plasma of septic patients (e.g. IL-6, TNF-α, 
IL-1β, IL-8) [145, 164, 165]. Furthermore, monocyte-induced activation of the 
coagulation system, combined with a general cytokine-mediated impairment of anti-
coagulation mechanisms, cause small capillaries to be blocked by accumulative 
numbers of microthrombi [144, 147]. In severe cases, this can lead to disseminated 
intravascular coagulation (DIC), and in turn, the disruption of normal coagulation, as 
platelets and coagulation proteins are consumed [166]. Pro-inflammatory cytokines 
also induce nitric oxide, which contributes to causing tissue hypoxia, a fall in blood 
pressure and ultimately the generation of organ dysfunction when sepsis progresses into 
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severe sepsis and septic shock [147, 148]. Finally, a link between elevated levels of 
monocyte-derived cytokines and sepsis-like symptoms has been demonstrated in mice 
using intravenous injections of TNF-α [167]. The prompt neutralization of such 
injected TNF-α prevented these symptoms from occurring, despite the same mice 
having an ongoing bacteremia [168].   
 
 
2.5.2 The anti-inflammatory phase of sepsis 
 
While universally accepted that the onset of sepsis embraces an intense pro-
inflammatory response, it is also well documented that, as sepsis progresses, the 
immune system can become overly anti-inflammatory [144, 149, 169]. This parallel 
counteraction, also referred to as the compensatory anti-inflammatory response 
syndrome (CARS) has been the focus of much attention in the last 15 years and many 
researchers believe that the immunological consequences of CARS are the main 
obstacles in reducing the high mortality rate associated with sepsis [170]. Although a 
small group of patients, suffering from particularly aggressive forms of infections, will 
rapidly die due to an early, one-sided phase of “cytokine storm”, this is not the typical 
sepsis scenario [151]. Instead, the majority of patients survive the initial phase only to, 
a few days later, transit into an anti-inflammatory state generated to counterbalance the 
initial, pro-inflammatory environment [144, 151]. As a consequence, most septic 
patients will with time display features that are indicative of being immunosuppressed, 
unable to eradicate their primary infection and susceptible to new, often hospital-
acquired secondary infections [144]. The exact mechanisms behind this state of hypo-
inflammation, also referred to as “immunoparalysis”, are currently not understood 
although they appear to involve an increased production of cytokines such as IL-10, IL-
13 and TGF-β [149, 171]. Nonetheless, a number of immunological defects have been 
reported to coincide with its manifestation and some are suggested to act as 
contributing factors in its development. Firstly, based on the findings in autopsies 
performed 30-90 minutes post mortem, death in a late stage of sepsis appears to be 
linked to a widespread apoptosis in the spleen of mainly CD4+ T cells and B cells 
[169]. This loss supposedly contributes to immunoparalysis by depleting necessary 
effector functions of adaptive immunity during a time period when it is especially 
needed. In addition, surviving immune cells, such as macrophages, are suggested to 
further add to the suppression through phagocytosis of the apoptotic cells left behind, a 
process that, as described in earlier sections, pushes these cells toward an M2 
phenotype and the production of more anti-inflammatory cytokines [108]. Secondly, 
monocytes isolated from septic patients have been shown to display a diminished in 
vitro capacity to secrete pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) in response 
to TLR-ligands [172-178]. Interestingly, this reduced capacity reportedly coincides 
with an increased or unaffected capacity for secreting anti-inflammatory cytokines such 
as IL-10 [176-178]. As a result, septic monocytes are said to have been reprogrammed 
into a state of “endotoxin tolerance” that reduces the patient’s ability to combat 
microorganisms [60]. The degree of this impairment may reflect sepsis-induced 
immunoparalysis and has been linked to a poor outcome/prognosis [173]. Thirdly, in 
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addition to an altered cytokine secretion profile, monocytes from septic patients are 
impaired in terms of antigen presentation as indicated by their diminished expression of 
the MHC class II molecule HLA-DR [179-181]. A persistent reduction in the 
expression of HLA-DR (<40% positive monocytes, compared to normal values of 
>90%) has been correlated with higher mortality and with an increased likelihood of 
developing secondary nosocomial infections [182, 183].  
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3 AIMS OF THESIS 
 
With this background in mind we initiated a project to investigate TLR-induced 
cytokine secretion by monocytes in septic patients and healthy controls using ELISpot 
and (or) the fluorescence based FluoroSpot technique. Due to the capacity of these 
methods to measure and establish cytokine secretion at the single cell level, we 
hypothesized that they would provide us with a novel perspective on monocytes and 
neutrophils and the role of these cells in the pathophysiology of sepsis. 
    
Specific aims: 
 
 
I. To determine the TLR4-induced cytokine profile of isolated granulocytes 
and mononuclear cells derived from healthy donors using ELISpot. 
 
 
II. To elucidate the relationship between monocyte populations isolated from 
healthy individuals secreting different cytokines in response to TLR-ligation 
using the FluoroSpot technique.  
 
 
III. To analyze if circulating monocytes contribute to the elevated plasma 
cytokine levels in septic patients and to evaluate the possibility of using 
ELISpot as a tool in the diagnosis and stratification of sepsis. 
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4 MATERIALS AND METHODS 
 
A description of the methods used in paper I-III is given below. All studies were 
approved by the ethics committee at the Karolinska Institutet.  
 
 
4.1 ISOLATION OF PBMC (PAPER I-II) 
 
Blood samples from healthy donors were collected by venipuncture into citrate blood 
collection tubes and subsequently mixed with an equal volume of PBS. The mixture of 
blood/PBS was layered on top of Ficoll-Paque PLUS and centrifuged 400×g for 30 
minutes. PBMCs were retrieved from the interface, washed twice in cell culture 
medium and diluted to the desired cell concentration. 
 
 
4.2 ISOLATION OF GRANULOCYTES (PAPER I) 
 
Following density gradient separation of PBMC using Ficoll-Paque PLUS, the 
remaining cell pellet was resuspended in PBS to its original starting blood volume and 
layered on top of Polymorphprep. After centrifugation at 600×g for 30 minutes the 
band of granulocytes was retrieved, mixed with two volumes of PBS and washed twice 
in cell culture medium. Following the removal of erythrocytes through hypotonic lysis, 
cells were again washed twice and suspended in cell culture medium. Viability was 
checked using trypan blue exclusion and purity was assessed by light microscopy of 
Türk stained cells. In addition, the granulocytes were checked for purity in flow 
cytometry using forward side scatter analysis. Cells suspended in cell culture medium 
were added to the flow cytometer and 50000 events were acquired. Based on cellular 
size and granularity, an estimated number of contaminating PBMC within the 
granulocyte preparation was obtained.    
 
 
4.3 DEPLETION OF CD14 POSITIVE CELLS (PAPER I) 
 
In order to investigate the cellular source of cytokines secreted by mononuclear cells in 
response to LPS, CD14-positive monocytes were depleted from PBMCs using BD 
IMag™ anti-human CD14 magnetic particles. In brief, freshly isolated PBMCs were 
centrifuged and incubated with the anti-CD14 magnetic particles for 30 minutes. The 
mixture was then carefully diluted in 2ml of cell culture medium and placed in the BD 
magnet. After 10 minutes, unbound cells depleted of monocytes, were carefully 
removed and washed in cell culture medium. For maximum depletion, the process was 
repeated once.  
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4.4 ISOLATION OF MONOCYTES (PAPER II) 
 
Monocytes were enriched using the RosetteSep isolation technique from Stemcell™ 
Technologies. Freshly drawn, citrated blood was incubated for 10 min with the 
monocyte enrichment cocktail containing bifunctional antibody complexes with a 
combined specificity for glycophorin A expressed on erythrocytes and cell surface 
markers expressed on T cells (CD2, CD3, CD8), B cells (CD19), NK cells (CD56, 
CD2), granulocytes (CD66b) and dendritic cells (CD123), respectively. Following 
incubation at room temperature, the mixture was layered on top of Ficoll-Paque PLUS 
and centrifuged 1200×g for 20 minutes. Through the formation of antibody crosslinks 
between glycophorin A on the erythrocytes and CD markers on the unwanted cells, 
non-monocytic cells were removed as heavier units of “immunorosettes” by density 
gradient separation. The enriched monocytes were retrieved from the Ficoll interface, 
washed twice and suspended in cell culture medium. 
 
 
4.5 ISOLATION OF CD16+ MONOCYTES (PAPER II) 
 
CD16+ monocytes were isolated in a two-step procedure using a specialized kit (CD16+ 
Monocyte Isolation Kit) from Miltenyi Biotech based on antibodies conjugated to 
magnetic MicroBeads. First, PBMCs were incubated with a mixture of buffer 
(PBS/0.5% BSA/2mM EDTA), FcR-blocking solution and magnetic MicroBeads 
coated with antibodies specific for granulocytes (anti-CD15) and NK-cells (anti-
CD56). After incubation for 15 minutes at 8°C, cells were washed in buffer and added 
to a prepared LD column placed in the Miltenyi magnet. PBMC depleted of NK-cells 
and granulocytes, were collected in the flow-through fraction. After centrifugation, 
these cells were then further incubated with a mixture of buffer and MicroBeads coated 
with anti-CD16 antibodies. After incubation for 15 minutes at 8°C, cells were again 
washed in buffer and added to a newly prepared MS column. This time, the cells of 
interest, i.e. CD16+ monocytes, were retained on the column, whereas cells passing 
through consisted of classical monocytes (CD14+CD16-) and remaining T and B cells. 
After rinsing with buffer, the column was removed from the Miltenyi magnet and 
placed in a suitable collection tube. Using 1ml of added buffer CD16+ monocytes were 
then pushed into the collection tube using the supplied plunger. In order to obtain a 
higher level of purity, the cells were again added to a freshly prepared MS column and 
the procedure repeated. Finally, the CD16+ monocytes were washed twice and 
suspended in cell culture medium to the desired concentration.    
 
 
4.6 ISOLATION OF LEUKOCYTES USING DEXTRAN (PAPER III) 
 
In paper III, cells were isolated by mixing citrated whole blood with an equal volume of 
PBS containing 2% dextran. After 15 minutes of incubation at room temperature a 
majority of red blood cells had sedimented to the bottom of the tube. The top buffy 
coat, containing total leukocytes, was retrieved and cells were counted in Türk and in 
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trypan blue. After centrifugation for 8 min at 250×g, the supernatant was removed and 
stored for further analysis by Luminex, and the cell pellet was resuspended in cell 
culture medium to the desired concentrations of 2.5×106 and 1.5×105 cells per ml. Cells 
were then added to the ELISpot plate and incubated overnight in the presence or 
absence of stimuli. 
 
 
4.7 ELISPOT ASSAY (PAPER I-III) 
 
The ELISpot technique was employed for detection of cytokine secreting cells in 
isolated populations of human PBMCs, granulocytes, enriched monocytes and total 
leukocytes, respectively. Ethanol pre-treated polyvinylidene fluoride membrane plates 
were coated with antibodies recognizing the cytokine of interest. Isolated cells were 
subsequently added at desired cell concentrations to wells containing medium, with or 
without stimuli, and incubated for 20 hours at 37°C in 5% CO2. The next day, cells 
were removed by washing the plates in PBS and the secreted cytokines were detected 
using biotinylated detection antibodies in combination with streptavidin (SA) 
conjugated to alkaline phosphatase (ALP) and finally developed with substrate. After 
drying the plates, spots, each corresponding to one single secreting cell, were counted 
using an ELISpot reader. 
 
 
4.8 ELISA ASSAY (PAPER I)  
 
Concentrations of IL-6, TNF-α and IL-1β were measured by ELISA using supernatants 
derived from LPS-stimulated granulocytes cultured at varying cell concentrations in 
uncoated ELISpot plates. The ELISpot plates had prior to the experiment been 
activated by ethanol, washed five times in sterile water and finally blocked in cell 
culture medium for 30 minutes before the isolated granulocytes were added. After 20 
hours of incubation, supernatants were retrieved and analyzed in pre-coated ELISA kits 
according to the manufacturer’s instructions.      
 
 
4.9 FLUOROSPOT ASSAY (PAPER II) 
 
The FluoroSpot technique was used to analyze single cells secreting two cytokines 
simultaneously. Ethanol-activated, low-fluorescent polyvinylidene fluoride membrane 
plates were incubated overnight with either a single or a combination of two capture 
antibodies directed against the following cytokines: IL-6, MIP-1β, TNF-α, GM-CSF, 
IL-1β, IL-10, IL-12p40. The next day, plates were washed five times with PBS and 
after blocked with cell culture medium, fresh medium with or without ligands for TLR2 
(LTA) or TLR4 (LPS) was added. Finally, enriched monocytes were added to the 
plates at desired cell concentrations and incubated for 20h at 37°C in 5% CO2. The 
following day, cells were removed by washing five times in PBS and secreted 
cytokines were detected using FITC-conjugated detection antibody to IL-6 or IL-1β in 
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combination with biotinylated antibodies against MIP-1β, TNF-α, GM-CSF, IL-1β, IL-
6, IL-10 or IL-12p40. After 2 hours of incubation, plates were washed as above and 
incubated with a mixture of streptavidin conjugated with red fluorophore and anti-FITC 
antibody conjugated with green fluorophore. Following incubation for 1 hour, plates 
were again washed and the plastic underdrain lining the backside of the FluoroSpot 
plate was removed. Fluorescence enhancer was added for 10 minutes after which the 
plates were carefully emptied and left to dry protected from light. Analysis and 
counting of spots were performed using a two-filter FluoroSpot reader. 
 
 
4.10 FLOW CYTOMETRY (PAPER II) 
 
Monocytes, depleted of contaminating erythrocytes and resuspended in cold FACS 
buffer (PBS supplemented by 0.02% NaN3 and 0.5% FCS), where analyzed for 
expression of CD3, CD14, CD19, CD56 and CD16 by incubating 4×105 cells in 50µl of 
cold FACS buffer mixed with either 10µl of anti-human CD3-PE, 20ul of anti-human 
CD14-PE, 20µl of anti-human CD19-PE, 10µl of anti-human CD56-PE or 5µl of anti-
human CD16-Alexa488. The double staining for CD14 and CD16 was performed by 
combining 20µl anti-human CD14-PE, 5µl anti-human CD16-Alexa488 and 25µl of 
FACS buffer. The level of non-specific staining was checked using matched isotype 
controls. In case of the double staining, the principle of “fluorescence minus one” was 
used, i.e. the substitution of only one isotype control at a time [129]. After 15 minutes 
of incubation at 4°C protected from light, cells were washed twice in cold FACS 
buffer, put on ice and analyzed in a flow cytometer.          
 
 
4.11 LUMINEX ASSAY (PAPER III)  
 
Plasma samples from the 38 enrolled patients, 32 healthy controls and 9 human 
endotoxemia volunteers were analyzed for concentrations of IL-6, TNF-α, GM-CSF, 
IL-1β, IL-10 and IL-12p40 using a Milliplex kit from Millipore based on the multiplex 
Luminex™ technology. The analyses were carried out by an outside commercial 
provider according to the manufacturer’s protocol. 
 
 
4.12 INJECTION OF ENDOTOXIN INTO HEALTHY VOLUNTEERS (PAPER 
III) 
 
Healthy male volunteers (n=9) were administered an intravenous bolus injection of 
purified endotoxin at a dose of 40 EU/kg body weight. Blood samples were retrieved 
before, 30 min and 150 min post injection. Total leukocytes were isolated using dextran 
sedimentation, plasma saved for Luminex analysis and cells analyzed in ELISpot as 
described previously. 
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4.13 PATIENTS (PAPER III) 
 
38 patients with suspected sepsis and 32 healthy controls were enrolled into the study. 
For three of the patients, a definitive diagnosis of sepsis could not be made and were 
therefore excluded. In addition, a differential cell count could not be established for 
three patients and two controls. Thus, 32 septic patients, categorized as having sepsis 
(6%), severe sepsis (19%) and septic shock (75%) were included in the study in paper 
III. The median age of these patients were 65 years (range 27-86 years) with an 
approximately equal distribution of men (49%) and women (51%). For all patients, the 
estimated time period between the first signs of sepsis and study blood sampling ranged 
from 9-337h (median 48h).  
 
4.14 STATISTICAL ANALYSIS (PAPER I-III) 
 
In paper I and II, differences between unstimulated and TLR-stimulated cells were 
evaluated by applying the non-parametric Wilcoxon signed rank test using SPSS 16.0 
software. In paper III, statistical analysis was performed using Graphpad Prism v.5 
software and the Mann-Whitney U test. In addition, Spearman or Pearson's method was 
used for correlation analysis. Differences were in all cases considered significant for 
p<0.05. 
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5 RESULTS AND DISCUSSION 
 
 
5.1 PAPER I - ELISPOT ANALYSIS OF LPS-STIMULATED 
LEUKOCYTES: HUMAN GRANULOCYTES SELECTIVELY SECRETE 
IL-8, MIP-1BETA AND TNF-ALPHA 
 
The coordinated production of cytokines following TLR4 activation has been studied 
previously in both PBMCs and granulocytes [184-190]. While earlier reports have 
typically employed cytokine detection techniques such as ELISA, intracellular cytokine 
staining in combination with flow cytometry (ICS) and RT-PCR, we here used the 
ELISpot technique. Principally, this technique combines the advantage of ELISA, by 
looking at what is truly secreted from the cells, with that of ICS, which permits analysis 
at the single cell level [191, 192]. Thus, the technique provides information not possible 
to obtain by the other assays. Moreover, as the cytokine of interest is captured 
immediately at the site of the producing cell, ELISpot is, compared to ELISA, less 
impaired by factors such as soluble receptors, protease activity and uptake of cytokines 
by surrounding receptor-bearing cells [193]. Finally, the ELISpot assay typically 
requires fewer cells for analysis, and data from studies of antigen-specific T cells have 
often demonstrated a very high sensitivity [139].  
 
With the ultimate intention to use this assay to analyze samples from sepsis patients, we 
first needed to establish the cytokine profiles of the blood cells most likely to become 
activated under septic conditions, i.e. monocytes and granulocytes. Like many others, 
we used LPS as a model PAMP for TLR4 receptor stimulation. For the investigation, 
PBMC (5000 cells per well) were incubated for 20 hours in ELISpot plates with or 
without LPS followed by an analysis of cytokines known to be produced in response to 
LPS (IL-1β, IL-6, IL-8, IL-10, IL-12p40, TNF-α, MIP-1β and GM-CSF).   
 
As seen in Figure 5, the frequency of secreting cells varied considerably depending on 
what cytokine that was analyzed. IL-6, IL-8, TNF-α and MIP-1β secreting cells 
displayed the highest frequencies after stimulation (average range 9.6-10.5% of 
PBMC). In contrast, IL-1β and GM-CSF were produced by smaller populations (5.5-
6.3%) whereas IL-10 and IL-12p40 were produced by only a small fraction of the cells 
(1.2-1.6%). These frequencies of secreting cells were surprisingly consistent between 
different donors suggesting the existence of a relatively fixed population of cells that 
responded in a predefined manner. 
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Figure 5.  
ELISpot analysis of isolated PBMC (5000 cells/well) incubated for 20 hours in the absence or 
presence of LPS (100 ng/ml) and analyzed for the secretion of IL-8, TNF-α, MIP-1β, IL-6, IL-
1β, GM-CSF, IL-12p40 and IL-10. Values represent the mean ± range of six individuals. 
Differences were considered significant for p<0.05 (*).  
 
In contrast to the potent cytokine secretion seen by the LPS-stimulated PBMC, little or 
no spontaneous production was observed for several of the cytokines when cells were 
cultured in medium alone (IL-1β, IL-6, IL-12p40 and GM-CSF). Also in the instances 
where a cytokine was secreted by a substantial number of unstimulated cells (IL-8, 
MIP-1β and TNF-α), LPS had a clear stimulatory effect as reflected by the increased 
size and intensity of spots. 
 
With LPS being recognized as a potent activator of monocytes and with the maximum 
number of secreting cells (i.e. around 10% for IL-8, TNF-α, MIP-1β and IL-6) roughly 
corresponding to the expected frequency of monocytes in PBMC, we repeated the 
experiments after having removed the monocytes using anti-human CD14-coupled 
magnetic beads. This way we could confirm that monocytes were indeed responsible 
for all or almost all of the cytokine secretion observed. With this knowledge and the 
fact that the frequencies of secreting cells showed little variation between individuals, 
we assumed that it would be quite possible to sort monocytes into subpopulations based 
on their cytokine profiles. This aspect was further studied in paper II.     
  
While PBMC is the leukocyte fraction most commonly used in immunological 
research, granulocytes comprise the bulk of leukocytes in the blood and consist of a 
dominating population of neutrophils (>95%) and smaller populations of eosinophils 
and basophils. Neutrophils have typically been described as short-lived phagocytic 
effector cells with an abundance of pre-stored anti-microbial factors but with limited 
capacity to synthesize new proteins [81]. In line with this, neutrophils harbor a 
comparatively small endoplasmic reticulum and contain fewer ribosomes in their 
cytoplasm than most other cell types [86]. Nonetheless, during the 1990s, neutrophils 
were shown to possess de novo cytokine-synthesizing capabilities in vitro in response 
to pathogenic factors such as LPS [82]. Although it was recognized that the amount of 
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cytokine produced by each neutrophil was limited, their presence in large numbers at 
infectious sites suggested that they could be a much more influential and 
immunologically important cell type than what had previously been acknowledged 
[75]. However, from a methodological viewpoint, these discoveries have remained 
controversial and further reports on cytokine production by neutrophils have been 
inconsistent [86]. Since neutrophils produce low amounts of cytokine per cell, large 
numbers of isolated granulocytes must be cultured together with LPS in order to 
accumulate amounts of cytokines measureable by ELISA, the technique most 
frequently used. As a result, the analysis becomes highly susceptible to the presence of 
contaminating cells (e.g. monocytes), something that is not easily discernible with the 
ELISA technique.  
 
Based on previous experiences of the ELISpot technique in analyzing T cells, we 
thought that this would present an ideal method as, instead of measuring the 
accumulated amount of cytokine in a cell supernatant with the potential drawbacks 
discussed above, it provides information about the frequency of secreting cells. To test 
this, granulocytes were purified and 5000 cells per well were incubated with or without 
LPS for 20 hours in ELISpot plates and analyzed for the same panel of cytokines as 
previously done for PBMC. As expected, a large proportion of the added cells secreted 
IL-8 and MIP-1β, two chemokines known to be secreted by neutrophils [86]. TNF-α-
producing cells were also detected, although at lower frequencies (Figure 6). In fact, the 
percentages of TNF-α spots were so low that we could not exclude that the production 
could originate from the minor populations of eosinophils and/or basophils [194, 195]. 
However, apart from a few strong spots, reminiscent of those seen for monocytes, we 
were unable to detect granulocyte-derived secretion of IL-1β, IL-6, IL-10, IL-12p40 or 
GM-CSF (Figure 6). 
 
  
Figure 6. 
ELISpot analysis of isolated PMN (5000 cells/well) incubated for 20 hours in the absence or 
presence of LPS (100 ng/ml) and analyzed for the secretion of IL-8, TNF-α, MIP-1β, IL-6, IL-
1β, GM-CSF, IL-12p40 and IL-10. Values represent the mean ± range of six individuals (IL-8, 
TNF-α, MIP-1β, IL-6, IL-1β, GM-CSF), five individuals (IL-10) and four individuals (IL-
12p40). Differences were considered significant for p<0.05 (*). 
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While these observations differ from several reports describing a multitude of cytokines 
being produced by granulocytes, they are in agreement with reports showing a much 
more restricted cytokine secretion profile for these cells [86, 189]. These two latter 
reports both used highly purified preparations of granulocytes in combination with 
careful interpretations of their ELISA measurements. Similar to us, these investigators 
have demonstrated a lack of IL-6 and IL-1β production by granulocytes. However, they 
also disqualified the small amounts of TNF-α detected in their granulocyte cell 
supernatants as being derived from contaminating mononuclear cells. To elucidate this 
further and to highlight possible differences in outcome between ELISA and ELISpot 
we investigated the production of TNF-α as well as IL-6 and IL-1β using both methods 
in parallel. For this purpose, isolated granulocytes were incubated for 20 hours with or 
without LPS at increasing cell numbers in ELISpot plates. The plates used for ELISpot 
were run as normal whereas the plates used to generate supernatants for ELISA 
measurements were without coating antibody. As expected, ELISpot was able to detect 
granulocyte-derived TNF-α spots already at 1000 cells per well. In contrast, IL-6 and 
IL-1β were either not detected at all or only in the form of a few strong spots. In 
ELISA, however, detectable amounts of cytokine in the cell supernatants were found 
first at >50.000 cells per well. Moreover, at this concentration, an interesting dichotomy 
in results between ELISA and ELISpot became apparent. Thus, while IL-6 and IL-1β 
were secreted by a very limited number of cells, much higher spot numbers were seen 
for TNF-α. However, the results from the ELISA were essentially reversed with the 
highest concentrations observed for IL-6 followed by IL-1β and lastly TNF-α. 
Accordingly, had the experiment only been interpreted based on the ELISA 
measurements, one had most likely arrived at a different conclusion regarding the 
cytokine-secreting capacity of granulocytes. 
 
In summary, the findings in paper I demonstrated that LPS stimulation of granulocytes 
resulted in a differential production of cytokines. By using the ELISpot technique we 
could demonstrate that several cytokines previously reported to be produced by 
granulocytes were likely to be the result of contaminating monocytes. The fact that two 
of the granulocyte-produced cytokines, IL-8 and MIP-1β are potent chemokines 
indicates that the primary function of granulocytes may indeed be to attract other 
immune cells to the infectious site and hereby promote the inflammatory process [88]. 
We also showed that monocytes are the principal cells responsible for the cytokine 
secretion observed in LPS-stimulated PBMC. While the cytokine profile of stimulated 
monocytes contained a number of both pro- and anti-inflammatory cytokines it was at 
the same time clear that they displayed a quite consistent pattern among different 
donors regarding the frequency of cells secreting certain cytokines. This may suggest 
that monocytes can be split into subpopulations based on their cytokine profiles. The 
broad cytokine producing capacity of monocytes on the other hand shows that these, in 
addition to displaying chemotactic activity, also serve as stimulatory and/or inhibitory 
regulators of other immune cells. Thus, monocytes/macrophages seem to be likely 
candidates to participate in creating the imbalance in the production of cytokines, 
suggested to be associated with sepsis. 
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5.2 PAPER II- FLUOROSPOT ANALYSIS OF TLR-ACTIVATED 
MONOCYTES REVEALS SEVERAL DISTINCT CYTOKINE-
SECRETING SUBPOPULATIONS 
 
Despite the great functional diversity of cells originating from monocytes (e.g. 
macrophages, dendritic cells and osteoclasts), only three distinct subpopulations of 
monocytes have been clearly defined. As previously mentioned these are the classical, 
non-classical and intermediate monocytes [129]. While this division has been 
universally accepted as the basis of monocyte heterogeneity, it has been difficult to 
ascribe any clear in vivo function to these subsets [196]. It is also evident from other 
studies that monocytes display further phenotypic heterogeneities, both in their 
expression of cell surface markers and also in their capacity to produce and secrete 
various cytokines [132, 197]. 
 
In view of these results and with cytokines playing such a critical role in all aspects of 
immunity, we wanted to further investigate the cytokine secretion profile of monocytes 
to see if we could find a consistent pattern of secretion that could provide a basis for a 
functional division of these cells. Such cytokine-based subclassification has been done 
for T cells and has been instrumental for the understanding of the functional 
differentiation between T cell subsets [23].  
 
To investigate this, monocytes from healthy volunteers were enriched using negative 
selection. While this approach resulted in a lower purity of isolated monocytes than 
what is typically achieved with positive selection, it has the significant advantage of 
leaving cells “untouched”. Thus, compared to positive selection, no bias in selection of 
a particular type of monocyte or steric hindrance of the TLR co-receptor CD14, the 
most common target for monocyte isolation, is introduced [127, 131, 132] [137]. 
Consequently, the monocytes investigated in paper II consisted of all three 
subpopulations, i.e. the classical, the intermediate and the non-classical monocytes, in 
essentially the same proportions as found in blood. Furthermore, we extended the 
number of stimuli and, besides LPS (TLR4), we also included LTA, a TLR2 ligand 
derived from gram-positive bacteria. For the analysis we used the novel FluoroSpot 
assay as this allowed the simultaneous analysis of more than one cytokine and hereby 
provided a more informative picture of the cytokine profiles [198].     
  
When we analysed the enriched monocytes in a single-color FluoroSpot, a similar 
pattern of cytokine secretion was observed as was previously seen for PBMC. Thus, 
following stimulation with either LPS or LTA, the cells produced IL-6 (average 
percentage of responding cells: 32.5%), TNF-α (39.2%), MIP-1β (30.1%), IL-1β 
(25.9%), GM-CSF (9.1%), IL-10 (1.3%) and IL-12p40 (1.2%) (Figure 7). 
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Figure 7. 
(A) Single-colour FluoroSpot analysis of enriched monocytes (1000 cells/well) incubated for 20 
hours in the absence or presence of LTA (500ng/ml) or LPS (50ng/ml) and analyzed for the 
secretion of IL-6, TNF-α, MIP-1β, IL-1β and GM-CSF using 1000 cells/well (A) or for the 
secretion of IL-10 and IL-12p40 using 3000 cells/well (B) Values represent the mean ± range of 
six individuals analyzed (n=6). Differences were considered significant for p<0.05 (*). 
 
Based on the number of secreting cells, a tentative division into three subgroups 
composed of high frequency responders (IL-6, IL-1β, TNF-α and MIP-1β), moderate 
frequency responders (GM-CSF) and low frequency responders (IL-10 and IL-12p40) 
could be made. When comparing responses to the two different TLR-ligands the 
number of monocytes secreting IL-6, MIP-1β and GM-CSF were similar independent 
of whether LTA or LPS was used for stimulation. However, for the cytokines IL-1β, 
TNF-α, IL-10 and IL-12p40 a modest but significant difference was observed, i.e. LPS 
generally stimulated more cells compared to LTA (Figure 7). As TLR4 is unique by 
signaling through both the Myd88- and TRIF-dependent pathways [41], these results 
may reflect the activation of the two intracellular pathways in parallel as compared to 
the single Myd88-dependent activation achieved through TLR2. Interestingly, this 
additional signaling only seemed to pose a positive effect on the secretion of some 
cytokines (IL-1β, TNF-α, IL-10 and IL-12p40) but not on others (IL-6, MIP-1β and 
GM-CSF). 
 
In our study, antibodies to IL-6 and IL-1β were available for detection with green 
fluorescence and each of these could be combined with red fluorescence detection for 
all the other cytokines. This way, we could investigate to what extent monocytes 
secreting IL-6 or IL-1β also secreted TNF-α, MIP-1β, IL-1β, GM-CSF, IL-10 or IL-
12p40. In total, the pattern of co-secretion was evaluated through eleven different 
combinations of two-color FluoroSpot.  
 
In the case of monocytes secreting TNF-α, the great majority also simultaneously 
produced IL-6 and IL-1β, displaying a secretory overlap ranging from (on average) 65-
83% in response to both LTA and LPS. However, when IL-1β and IL-6 were tested in 
combination with the two cytokines MIP-1β and GM-CSF a different relationship was 
observed. While the majority of IL-6-secreting monocytes also secreted MIP-1β (>75% 
average) only a minority of the IL-1β-secreting cells secreted this cytokine (<38% 
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average). Similarly, of the GM-CSF-secreting monocytes the great majority (>83% 
average) also secreted IL-6 while less than 30% co-secreted IL-1β. This observation of 
a high percentage of co-secretion for IL-6 and a low percentage for IL-1β was similar 
in relation to IL-10 and IL-12p40. Finally, when combining IL-6 and IL-1β, a minority 
of the cells secreting IL-6 also secreted IL-1β (average range 23-40%). Figure 8 below 
summarizes the relationship in FluoroSpot for IL-6/GM-CSF, IL-1β/GM-CSF and IL-
6/IL-1β.  
Figure 8. 
FluoroSpot analysis of cytokine co-secretion by enriched monocytes. Cells (1000/well) were 
incubated for 20 hours and analyzed for the co-secretion of (A) IL-6/GM-CSF, (B) IL-1β/GM-
CSF and (C) IL-6/IL-1β in response to LPS (50 ng/ml) or LTA (500 ng/ml).  By the use of 
FluoroSpot, each cytokine combination revealed three distinct cytokine-secreting 
subpopulations: monocytes secreting either cytokine (FITC or Cy3 labeled; green or red 
boxplots) or monocytes secreting both cytokines (yellow boxplots). Boxplots represent 
minimum, first quartile, median, third quartile and maximum and are based on six individual 
donors (n=6). 
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Overall, these results demonstrate that despite being incubated under identical culture 
conditions, individual monocytes responded differently to TLR2- and TLR4-
stimulation by secreting what appeared to be a predisposed set of cytokines. For each 
individual and combination of cytokines analyzed, a recurring pattern of co-secretion 
was detected as each responding monocyte could be categorized into one of three 
cytokine-secreting subpopulations (“FITC single”, “FITC+Cy3 double” or “Cy3 
single”). Furthermore, although variations existed between individuals and TLR-ligand, 
percentages of co-secretion were still fairly consistent, suggesting that predetermined 
subsets of monocytes do exist and that a sophisticated regulation in how these cytokine 
subsets are maintained within the immune system are in play. However, due to our 
analysis being limited to the detection of only two cytokines simultaneously, there was 
a natural restriction in our understanding of how these different subpopulations of 
monocytes correlated to each other. For example, we could not elucidate how the 
monocytes secreting GM-CSF related to the ones secreting TNF-α or whether the small 
population of monocytes co-secreting IL-1β and GM-CSF also secreted IL-12p40. 
Nonetheless, although the results in paper II only partially reveal what appears to be a 
complex arrangement, one can still speculate how these cytokine secretion patterns are 
formed. First, it is possible that monocytes could be marked by differences in their 
TLR-signal transduction pathways specific for TLR2 and TLR4. As an example, a 
subgroup of monocytes could harbor an increased quantity of certain MAPKs, allowing 
these cells to stabilize the translation of a more diversified number of cytokines in 
response to TLR-ligation [199]. The effect would essentially be monocytes secreting a 
wider repertoire of cytokines compared to others. Through subtle variations in the 
starting quantities of the different MAPKs, diversity in cytokine secretion would follow 
and manifest itself as the monocyte subpopulations observed by us in FluoroSpot. 
Alternatively, the cytokine subsets could also be the result of direct changes in the 
cellular expression of the genes coding for the cytokines investigated. In this case, 
TLR-signaling would pose no distinction in activation in one monocyte compared to 
another. Instead, individual monocytes would be predisposed towards secreting a 
particular set of cytokines as a result of direct epigenetic modifications to their genome 
[200]. In turn, these modifications could originate either at the level of monocyte 
progenitors in bone marrow, or through continued differentiation in the peripheral 
blood [11].    
 
Irrespective of the molecular basis behind these cytokine subsets, our results 
nonetheless indicate a diversity among monocytes that in complexity far exceeds a 
simple division of the cells into the three subsets of classical (~90%), intermediate 
(~5%) and non-classical (~5%) monocytes.  
 
In order to more specifically highlight this issue, we also purified the CD16+ monocytes 
for analysis in FluoroSpot (of IL-6/TNF-α, IL-6/MIP-1β, IL-6/GM-CSF, IL-6/IL-10 
and IL-6/IL-12p40). Apart from a small increase in the proportion of TNF-α, the 
CD16+ monocytes displayed a similar cytokine-secreting profile as the monocyte 
population as a whole. Simply put, if the intermediate and non-classical monocytes had 
been the predominant producers of TNF-α and/or IL-10 [119, 127], a much higher 
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frequency of such cytokine-secreting cells should have been seen when the proportion 
of CD16+ cells (~10% in total monocytes) was increased to ~88% in the specific 
experiment described above. Although the CD16+ monocytes were not separated into 
their respective subpopulations of intermediate and non-classical, our results still holds 
merit in disputing the practice of relating the expression of CD14 and CD16 to a 
specific type of TLR4-induced cytokine profile. Instead, we propose that other cell 
surface markers should be investigated as potential correlates of the cytokine secretion 
profile of monocytes to provide monocyte researchers with an additional and 
potentially better tool for exploring the function of these cells than what is currently 
being utilized. 
 
As touched upon above, a fundamentally important question is whether monocytes are 
equal when it comes to their ability to secrete different cytokines or whether 
monocytes, similar to T cells [100], fall into specialized subsets endowed with a 
particular type of function that is mirrored by their TLR-induced cytokine secreting 
capacity in vitro. Our findings in paper II not only strengthen the argument for a high 
degree of cytokine specialization within the population of monocytes, but they also 
contradict the official nomenclature of monocytes as being the functional identity of 
these cells. Nevertheless, open questions remain regarding the stability of these subsets, 
how they relate to the development of macrophages and whether or not they can be 
correlated to surface markers that are separate from CD14 and CD16.   
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5.3 PAPER III- CIRCULATING MONOCYTES ARE NOT THE MAJOR 
SOURCE OF PLASMA CYTOKINES IN PATIENTS WITH SEPSIS 
 
While several immunomodulatory therapies for treating sepsis, including the blocking 
or neutralization of pro-inflammatory cytokines, have been used in the clinic during the 
last two-three decades there has been little improvement in the rate of fatal outcomes in 
septic patients [201]. The reasons behind these failures have been suggested to stem 
from an incomplete understanding of the septic syndrome and by a lack of precise 
criteria for staging the patients’ immune status [202, 203]. One argument has been that 
while interventions intended to reduce inflammation may be suitable during the initial 
phases of sepsis, such treatments should not be given to those that have moved into a 
secondary state dominated by anti-inflammatory mechanisms [151, 169, 201]. In the 
trials performed, patients have been categorized according to the standard criteria for 
sepsis, i.e. severe sepsis or septic shock. However, while these definitions are 
universally accepted, they do not take into full account the differences in 
immunological status that are likely to exist between patients belonging to the same 
sepsis category [204]. Although a number of studies have tried to define patients as 
being in either an inflammatory or anti-inflammatory state based on cytokine levels in 
their plasma, it has not been possible to find a consensual correlation between a certain 
set of cytokines or other mediators and the different stages of sepsis [181, 205-208]. 
 
The lack of predictive diagnostic markers has typically been explained by the inherent 
heterogeneity in the etiology of sepsis in different patients and by the difficulties to 
stratify a disease process based on accumulated levels of cytokines in plasma [181, 203, 
209]. Partly due to this and partly due to other potential inadequacies of ELISA and 
Luminex measurements [139, 193, 209], we wanted to assess cytokine secretion in 
septic patients by looking at the cellular level. We hypothesized that measuring 
cytokine secretion at the single cell level directly ex vivo as possible by the ELISpot 
technique would give us a more accurate picture and allow for a better categorization of 
patients into either a hyper- or hypo-inflammatory state. If correct, ELISpot could this 
way provide valuable insight into the pathogenesis of sepsis and could potentially be 
used diagnostically to both identify sepsis at an early stage and to more accurately 
define the various stages of the disease. 
 
Thus, with the purpose of capturing a “snapshot” of the ongoing cytokine secretion, 
total leukocytes, isolated by dextran sedimentation, were incubated overnight in the 
absence or presence of LPS in ELISpot plates coated with capture antibodies against 
IL-6, TNF-α, IL-1β, GM-CSF, IL-10 and IL-12p40. Apart from being a very gentle 
method of isolating the cells, this protocol also allowed us to shorten the time needed 
for setting up our experiments. Counting the time used between drawing of the blood 
and starting incubation of the cells in the ELISpot plates, this ranged from 45-180 
minutes in all individuals analyzed. In total, 35 septic patients, 32 healthy controls and 
9 endotoxemia volunteers were evaluated in this study. Plasma samples from each 
individual were also collected and analyzed in Luminex for the same set of cytokines. 
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This way we were able to analyze both the spontaneous and the LPS-induced secretion 
in the different groups as well as compare these to the levels found in plasma. 
When first looking at the number of spontaneous spots generated by cells that were 
cultured overnight in medium alone, we could not observe any difference between 
patients and the healthy controls for any of the cytokines (Figure 9). 
 
 
Figure 9. 
Cytokine ELISpot and Luminex analysis (IL-6, TNF-α, IL-1β, GM-CSF, IL-10 and IL-12p40) of 
total leukocytes and plasma isolated from septic patients and healthy controls. The results of 
ELISpot are presented as the number of spots detected per 1000 monocytes analyzed, whereas 
concentrations in plasma are shown as pg/ml. Data is presented in the form of dot-plots with 
the horizontal bars indicating the median value of each group. For 3 patients and 2 healthy 
controls a differential blood count could not be established and they were therefore excluded 
from the analysis, resulting in a total cohort of 32 septic patients and 30 healthy controls. In the 
case of IL-10, the analysis was performed on a reduced number of patients (n=27) and healthy 
controls (n=27). Differences were considered significant for p<0.05 (*) using the Mann-
Whitney U test.  
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In fact, the number of cytokine-secreting cells in freshly cultured leukocytes was 
generally very low in both groups. Considering a supposed role of monocytes and their 
secreted cytokines as principle mediators of the septic syndrome, these results were 
quite surprising to us, especially considering that the concentrations of the same 
cytokines in plasma were significantly up-regulated at the time of sampling. Since 
monocytes can be activated by very low amounts of TLR-ligands [197] and the plasma 
of many septic patients reportedly contain up to 5 ng/ml of LPS [210], we had 
envisioned an increased number of in vivo activated, cytokine-secreting monocytes in 
the patients. Earlier studies of septic patients that also failed to detect increased 
cytokine-secretion in unstimulated cell cultures have typically employed ELISA for 
their measurements [172, 175, 211, 212].  We had anticipated that, given the higher 
sensitivity of the ELISpot, and by looking at the single cell level, we would get a result 
that corresponded better to the increased cytokine levels in plasma. It is of course 
possible that the monocytes, as a consequence of the in vitro handling once taken out of 
the patient, rapidly ceased their secretion of cytokines. However, we believe this is 
unlikely since TLR-activation typically elicits very powerful cytokine responses that 
are not easily terminated [213]. In support of this, we also showed in separate 
experiments that stimulation of whole blood samples from healthy donors with LPS, 
followed by leukocyte isolation using dextran, did not affect the capacity of the cells to 
produce and secrete cytokines (data not shown). Instead, we believe that the results 
reflect that monocytes, once activated in vivo, are quickly removed from the circulation 
by adherence to the endothelium [214, 215]. Although the monocytes in this state might 
not instantly extravasate into tissues, we speculate that they are nonetheless 
inaccessible to blood sampling via venipuncture.  
 
In contrast to the limited cytokine secretion by cells cultured in medium alone, the 
same cells added to ELISpot wells containing LPS resulted in an increased number of 
cytokine secreting monocytes both in patients and healthy controls (Figure 9). 
However, while the number of IL-6 and TNF-α spots/1000 monocytes were similar in 
the two groups, septic patients responded with a lower frequency of IL-1β, IL-10, GM-
CSF (p<0.001) and IL-12p40 (p= 0.03) secreting monocytes. Although most studies of 
sepsis have demonstrated a down-regulation in the amount of cytokines secreted by 
monocytes in response to LPS [172-178], our results in ELISpot highlights new aspects 
on this refractory or endotoxin-tolerant state. Firstly, the number of LPS-induced IL-6 
and TNF-α spots were similar in sepsis patients and controls, demonstrating that the 
sepsis-derived monocytes were indeed able to respond to LPS. This indicates that the 
intracellular signaling pathways necessary for secreting these two cytokines had not 
been significantly affected. In contrast, the frequencies of cells secreting IL-1β, IL-10, 
GM-CSF and IL-12p40 were lower in the septic patients. Thus, while the isolated 
population of monocytes had been properly activated through TLR4 to secrete IL-6 and 
TNF-α, they simultaneously lacked the ability to secrete another group of cytokines, 
suggesting a deficiency in the TLR4 signal transduction and/or secretory pathways 
specific for IL-1β, IL-10, GM-CSF and IL-12p40. In theory, increased levels of 
intracellular negative TLR-regulators described earlier in this thesis could explain this 
altered repertoire of cytokine secretion. Previous reports on monocytes in sepsis have 
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come to similar conclusions on monocyte TLR4-responsiveness as being 
“reprogrammed” [174]. However, while their results, in general, have pointed towards 
a strengthened anti-inflammatory profile with a decreased production of cytokines such 
as TNF-α and IL-6 but a maintained production of IL-10 [174], our data indicate the 
opposite with a sustained TNF-α and IL-6 production but a lowered number of IL-10 
secreting cells.         
 
Another hypothetical explanation for the observed changes in LPS-induced cytokine 
profile in septic patients could involve replacement of the monocyte population by 
another population of monocytes generated in a second wave of host defense. Recently, 
mice have been shown to harbor a reservoir of monocytes in the spleen that can serve 
exactly this purpose by rapidly restoring the monocyte population in situations of 
systemic inflammation [216]. If present in humans, such newly recruited monocytes 
would constitute a fresh pool of monocytes not likely to show evidence of exhaustion, 
but still be marked by changes in the way these cells respond to LPS in vitro. An 
increased proportion of such monocytes, as possibly seen in the samples of our study, 
could therefore be a sign of stimulated and more cytokine capable monocytes having 
moved out into tissues. This concept is supported by the fact that the change in the 
cytokine repertoire of septic blood monocytes could be negatively correlated with the 
patient’s individual SOFA score, suggesting a link between the “functional” 
composition of the monocytes in circulation and the degree of organ dysfunction 
(Figure 10). 
Figure 10. 
Analysis of the correlation between the SOFA score and the number of IL-1β - or GM-CSF-
secreting monocytes in response to LPS (spots/1000 monocytes). Differences were considered 
significant for p<0.05 (*) using the Spearman rank correlation coefficient.  
 
During the course of this study, we also had the opportunity to test cells from healthy 
individuals challenged with low doses of endotoxin (40 EU/kg). Blood samples were 
collected at three time points; before, 30 minutes after and 150 minutes after LPS 
infusion. In this way, we could control the starting point of the systemic inflammatory 
response and thereby increase our chances of “capturing” a population of in vivo 
activated monocytes from the circulation. However, in line with results in sepsis 
patients, we found few or no cytokine-secreting monocytes when cells were incubated 
in medium alone (Figure 10). This was in spite of elevated levels of the same cytokines 
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being readily detected in plasma after 150 minutes. At this time point, we also saw a 
dramatic reduction in the number of LPS-induced spots which, however, correlated to a 
corresponding reduction in the number of circulating monocytes (Figure 10).  
 
 
 
Figure 11. 
IL-6 ELISpot of leukocytes, IL-6 Luminex analysis of plasma and differential cell count on the 
percentage of monocytes in leukocytes isolated from healthy volunteers injected intravenously 
with low doses of endotoxin (40 EU/kg). Blood samples were retrieved before, 30 minutes and 
150 minutes post infusion. (A) Representative examples of IL-6 ELISpot following endotoxin 
administration. Cells (15,000 leukocytes/well) were incubated for 20h in the absence or 
presence of LPS. (B) Luminex analysis of IL-6 in plasma following endotoxin administration. 
(C) Percentages of monocytes in the isolated samples of leukocytes before, 30 minutes and 150 
minutes post infusion. Data represent the mean ± range of three individual donors. 
 
 
Collectively, these results went against our initial expectations, especially considering 
that blood samples harvested 30 minutes after the injection of LPS at least in theory 
should contain sufficient amounts of endotoxin to trigger the leukocytes both in the 
circulation and subsequently in the ELISpot wells. However, previous studies of the 
levels of endotoxin that remain in circulation post LPS infusion have been evaluated 
using the Limulus assay [217]. Using an equal dose of injected endotoxin (40EU/ kg) 
the study by Pajkrt et al only found minute amounts of LPS in the blood 30 minutes 
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post injection. Thus, considering the seemingly rapid removal of activated monocytes 
from the circulation and the numerous plasma proteins in vivo that are known to 
interact with LPS and modify its stimulatory activity, our negative results are not 
unreasonable. Furthermore, recent experiments in mice have demonstrated that cells of 
hematopoietic origin, compared to cells of non-hematopoietic origin, only play a minor 
contributing role in generating the increased plasma levels of IL-6 following LPS 
injection [218].  
 
In conclusion and contrary to our expectations, our results indicate that sepsis is not 
associated with an increased number of cytokine-secreting monocytes in the blood. 
Instead, the increase in cytokine levels seen in plasma from patients is likely generated 
by extravasated monocytes, macrophages and/or from other sources including activated 
endothelial cells and those of non-hematopoietic origin. However, as a manifestation of 
the disease, we could observe an altered cytokine profile in the septic monocytes after 
LPS stimulation in vitro. This was seen in the form of a lowered frequency of 
monocytes secreting IL-1β, IL-10, IL-12p40 and GM-CSF. This reduction was shown 
to correlate to the degree of organ dysfunction as measured by SOFA score. The 
correlation suggests that ELISpot analysis of these cytokines, similar to what has 
previously been shown for monocyte HLA-DR [181], could potentially be useful as a 
clinical tool for determining the immunological status of septic patients. 
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6 CONCLUSIONS 
 
As a leading cause of morbidity and mortality in critically ill patients, sepsis 
represents a major burden on healthcare resources worldwide [209]. In fact, medical 
costs for sepsis are expected to exceed $60 billion per year in the United States alone 
[219], a staggering amount that will only continue to rise as the population grows 
older and antibiotic resistance becomes more ubiquitous. Furthermore, there has been 
a disappointing level of improvement in the treatment of sepsis patients during the 
last few decades [201]. This is in spite of great efforts having been made to find better 
techniques for early diagnosis as well as novel strategies for therapeutic intervention, 
both of which have been key factors in improving the outcome of other disorders 
such as acute myocardial infarction, stroke, and trauma [220]. By understanding the 
early pathogenesis of these diseases, it has been possible to develop and test new 
means of therapy that have ultimately led to significant breakthroughs in treatment. A 
similar progression in sepsis would be highly valued. However, in the last two 
decades, the failures of several high-profile trials have made experts realize the need 
for a re-evaluation of the sepsis syndrome [4]. A better definition and real-time 
assessment of the immunological status characterizing the different stages of sepsis 
will here be of critical importance and hopefully allow both for improved diagnosis 
and treatment of this severe condition [202, 220].        
 
In this thesis, we developed and evaluated the highly sensitive ELISpot and FluoroSpot 
techniques for the measurement of a number of pro- and anti- inflammatory cytokines. 
With the ultimate purpose of investigating cells from sepsis patient, we first applied the 
techniques to study cytokine secretion by normal monocytes and granulocytes in 
response to TLR-ligation. This way, we could demonstrate the advantages and 
improved accuracy of establishing cytokine profiles at the single cell level compared to 
measuring cytokines in cell supernatants. In addition, we showed that monocytes, at 
least under the experimental conditions of the FluoroSpot assay, can be divided into 
cytokine-secreting subsets in response to TLR-stimulation and we believe that this type 
of categorization may represent a more relevant way of defining the heterogeneity and 
ultimately the function of these cells. Using blood cells from septic patients, we 
further demonstrated that, despite analyzing cytokine secretion at the single cell level 
in newly admitted patients presenting with severe sepsis and septic shock and with 
significantly elevated cytokine levels in their plasma, it was not possible to detect any 
cells expressing increased production of these biomarkers. We believe that this is due 
to that, once activated, the cells responsible for cytokine production are rapidly 
removed from the circulation by adherence to the endothelium and subsequent 
extravasation. Finally, while ELISpot analysis of leukocytes isolated from septic 
patients showed no signs of increased spontaneous cytokine secretion directly ex vivo, 
LPS-stimulation of these cells revealed a shift in the composition of the monocytes 
towards a more pro-inflammatory, less diverse, cytokine-secreting profile. This reduced 
repertoire of secreted cytokines could be correlated with the degree of organ 
dysfunction in these patients. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Ett infekterat sår aktiverar kroppens immunförsvar i form av en inflammationsreaktion. 
Denna mobilisering har som mål att försvara oss mot de bakterier som tagit sig in i 
såret. Det medfödda immunförsvaret spelar här en avgörande roll då dess immunceller, 
bland andra monocyter och granulocyter, innehar förmågan att känna igen 
bakteriefragment via så kallade Toll-lika receptorer och starta den inflammatoriska 
processen genom att producera viktiga signalproteiner kallade cytokiner. Cytokinerna 
signalerar till närliggande celler att en infektion påträffats, varvid de klassiska 
inflammationstecknen uppstår i det infekterade området; svullnad, rodnad och 
dunkande smärta.  
 
I normala fall läker infektioner av sig själva utan att det uppstår några komplikationer 
men i sällsynta fall kan bakterier eller fragment av dessa ta sig ut i blodet och orsaka 
sepsis (blodförgiftning). Detta är ett allvarligt sjukdomstillstånd där det medfödda 
immunförsvaret överreagerar och producerar för mycket cytokiner när bakterierna 
sprider sig i blodomloppet. Sepsis kännetecknas initialt av feber, frossa och ett påverkat 
allmäntillstånd, men kan i allvarligare fall snabbt övergå i livshotande yttringar såsom 
blodtrycksfall, organsvikt och medvetslöshet. Sjukdomen är komplex då den sägs bestå 
av två parallella faser där immunförsvaret först överaktiveras, och sedan trycks ner av 
efterföljande anti-inflammatoriska processer.   
 
Läkare har länge efterfrågat förbättrade möjligheter att tidigt kunna diagnostisera sepsis 
men även metoder för att i senare skeden av sjukdomsförloppet kunna klassificera 
sepsis utifrån patientens aktuella immunstatus. Syftet med den här avhandlingen var att 
undersöka cytokinproduktionen från monocyter och granulocyter, i både friska 
individer och i sepsispatienter, med hjälp av en känslig metod kallad ELISpot. Denna 
metod utgår från de isolerade cellerna och mäter frisättningen av cytokin i form av 
antalet producerande celler och inte, som de flesta andra tester, den totalamängd som 
sekreterats från ett okänt antal producerande celler. Härigenom kan man uppnå en sorts 
realtidsanalys på enskild cellnivå av vad som produceras just där och då. Vår 
förhoppning var att, genom att applicera denna metod på patienter med sepsis, kunna 
fånga en ögonblicksbild av cytokinproduktionen och på så sätt bättre kunna 
konkretisera sjukdomens olika faser.       
 
I det första delarbetet undersökte jag och mina kollegor cytokinproduktionen hos 
isolerade immunceller tagna från friska individer efter stimulation med ett 
bakteriefragment kallat lipopolysackarid (LPS). Vi behövde veta vilka cytokiner som 
sekreterades som svar på stimuli liksom vilka celler som stod för produktionen. Detta 
var viktigt att ta reda på inför testningen av ELISpot-metoden på sepsispatienter. Flera 
cytokiner undersöktes och ett återkommande mönster kunde urskiljas: Granulocyter 
producerade framförallt IL-8 och MIP-1β och en mindre andel av cellerna även det 
proinflammatoriska cytokinet TNF-α men däremot inget IL-6, IL-1β, GM-CSF, IL-10 
eller IL-12p40. Denna selektiva cytokinproduktion hos granulocyter skilde sig från 
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många tidigare publicerade arbeten där andra och mindre diskriminativa metoder 
använts. Bland de andra immuncellerna var det framför allt monocyter som svarade på 
LPS-stimulering. Dessa var också mycket mer kapabla än granulocyter och 
producerade alla de cytokiner som undersöktes. Antalet producerande monocyter skilde 
sig dock stort beroende på vilket cytokin som analyserades, och till exempel 
producerades både IL-10 och IL-12p40 av ca 10 gånger färre celler jämfört med TNF-α 
och IL-6, och ca 5 gånger färre jämfört med GM-CSF och IL-1β. Då dessa förhållanden 
i antalet cytokinproducerande monocyter var relativt stabila mellan olika individer, 
tyder detta på att monocyternas förmåga att producera dessa cytokiner var förutbestämt 
och på något sätt reglerades av immunförsvaret.    
 
I det andra delarbetet användes en ny form av fluorescensbaserad ELISpot-teknik 
kallad FluoroSpot. Med hjälp av denna kunde vi undersöka två olika cytokiner 
samtidigt från samma population av isolerade celler, istället för bara en såsom med 
ELISpot. Utöver LPS undersöktes även monocyternas cytokinproduktion som svar mot 
ett annat bakteriefragment kallat LTA. Som vi sett förut producerades de olika 
cytokinerna av olika antal monocyter men tack vare FluoroSpot teknikens fördelar fick 
vi nu även en inblick i hur monocyternas produktionen överlappade mellan olika 
cytokiner. Till exempel visade det sig att nästan alla monocyter som producerade GM-
CSF även producerade IL-6 medan endast en mindre andel uppvisade en samtidig 
produktion av IL-1β. Genom att kombinera analyserna från flera olika 
cytokinkombinationer i FluoroSpot kunde vi snabbt urskilja vissa distinkta och 
överlappande mönster för hur denna produktion var arrangerad och hur dessa mönster 
var relativt stabila från individ till individ. Studien ger på detta sätt en ny inblick i 
monocyternas kategorisering och den komplexitet som finns inbyggd i denna del av det 
medfödda immunförsvaret.  
 
I det sista delarbetet undersöktes och jämfördes cytokinproduktionen hos immunceller 
från 30 friska individer och 32 sepsispatienter med hjälp av ELISpot tekniken. Återigen 
testades samma panel av cytokiner som i de tidigare studierna: IL-6, TNF-α, IL-1β, 
GM-CSF, IL-10 och IL-12p40. Från det att blodet tappats från patienten till att cellerna 
isolerats och adderats till ELISpot för analys tog det cirka 1 timme. Vi hoppades 
därigenom kunna fånga en del av de monocyter som förmodats redan vara aktiverade i 
sepsispatienterna och på så sätt i realtid kunna studera och jämföra 
cytokinproduktionen hos patienter och friska individer liksom mellan patienter i olika 
stadier av sepsis. Trots att vi i flertalet patienter fann kraftigt förhöjda nivåer av fria 
cytokiner i blodet kunde vi dock aldrig se en höjning i antalet cytokinproducerande 
celler hos dessa. Det var alltså ingen skillnad mellan helt friska människor och 
allvarligt sjuka sepsispatienter vilket grusade vår förhoppning att med denna metod 
kunna konkretisera sjukdomens olika faser. När vi däremot stimulerade cellerna med 
LPS in vitro, ökade som förväntat antalet cytokinproducerande monocyter. Mönstret 
från denna cytokinproduktion var dock annorlunda i sepsispatienter jämfört med friska 
individer. Sålunda var antalet producerande celler signifikant lägre i patienterna för 
vissa av cytokinerna (IL-1β, GM-CSF, IL-10 och IL-12p40) medan de för andra 
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cytokiner (IL-6, TNF-α) var desamma i båda grupperna. Denna selektiva minskning 
visade sig korrelera med nivån av organsvikt bland sepsispatienterna. 
 
Sammanfattningsvis hoppas vi att studierna i denna avhandling kan bidra till en allmänt 
bättre förståelse av cytokinproduktionen hos såväl granulocyter som monocyter liksom 
visa på möjligheten att indela monocyter i funktionellt distinkta grupper baserat på 
vilka cytokiner de har förmågan att producera. Våra resultat från sepsispatienter 
indikerar vidare att den cirkulerande populationen av monocyter inte är den primära 
källan av sjukdomsframkallande cytokiner vid sepsis. Mycket tyder istället på att de 
celler som förmodas aktiveras vid sepsis mycket snabbt och effektivt elimineras från 
blodbanan genom att adherera till kärlväggarnas endotel och därefter genom s.k. 
extravasering försvinna ut i kringliggande vävnad. Denna insikt kan vara av betydelse 
för såväl framtagningen av ny och förbättrad sepsisdiagnostik som för möjligheten att 
utveckla nya strategier för behandling.   
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